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5ABSTRACT
Chlamydia pneumoniae is  a  very  common  intracellular  bacterium  in  humans.  It  causes
upper respiratory tract diseases, symptoms often occurring as normal seasonal flu.
C. pneumoniae is shown to be the causative agent of approximately 10% of community-
aquired pneumonia (CAP) cases. Pneumonia is one of the leading causes of death globally.
The treatment and hospitalization costs to the society are remarkable. There are antibiotics
to treat C. pneumoniae infections, but they are not without problems. One problem is the
overall increasing resistance which is associated with the use of broad-spectrum antibiotics.
As the diagnostic technology improves, and the pathogen can be specified in increasing
number of cases, there is a need for rational drug treatment with more selective, narrow-
spectrum antibiotics. With the targeted treatment, the development of resistant strains can
be delayed and the patient’s normal microbiota will be unharmed. Another problem with
the antibiotics currently in use is that C. pneumoniae can turn into a persistent form which
causes a chronic infection. This is associated with other chronic diseases, such as lung
cancer, cardiovascular diseases and multiple sclerosis (MS). The persistent form, in turn,
cannot be cured with current antibiotics.
In the present study, new antichlamydial compounds were discovered from plants and
natural product libraries. This thesis presents a new antichlamydial group of compounds,
dibenzocyclooctadiene lignans from the fruits of Schisandra chinensis (Turczaninov)
Baillon, i.e. Schisandra lignans. Cough and pneumonia are among the
ethnopharmacological uses of the extracts obtained from the fruits of S. chinensis. In this
work, the extract completely inhibited the growth of C. pneumoniae cardiovascular strain
CV6 and showed significant inhibition of the growth of a clinical isolate K7. The growth
inhibition of two chlamydial species, C. pneumoniae and Chlamydia trachomatis was dose
dependent and established with three different strains. These findings give raise to the
potential of the extract from S. chinensis berries as a source of antichlamydial compounds.
Schisandra lignans were shown to inhibit C. pneumoniae inclusion formation and
production of infectious progeny. One of the lignans, schisandrin B, inhibited
C. pneumoniae inclusion formation even when administered 8?hours post infection,
6indicating a target that occurs in the mid-phase of the intracellular infection cycle of
C. pneumoniae. Before infecting the host cells, the lignan-pretreated C. pneumoniae
elementary bodies had impaired ability to form inclusions. The structure–activity
relationship among the lignans was clear. Substitution and presence of methylenedioxy,
methoxy and hydroxyl groups in the structure of the lignans had a substantial impact on the
antichlamydial activity. In addition, the data suggest that the antichlamydial activity of the
lignans is not caused only by their antioxidative properties. None of the lignans inhibited
growth of seven other common metabolically active bacteria, suggesting a degree of
selectivity of the antichlamydial effect. The lignans were shown to be non-toxic to the host
cells, which is in line with the literature presenting these compounds.
Moreover, this work presents a novel strategy for lead discovery on C. pneumoniae. Ligand-
based  virtual  screening  (LBVS)  of  a  natural  product  library  with  the  ChemGPS-NP
chemography tool, followed by validation of the activity with in vitro antichlamydial assays
proved successful with a hit rate of 1.2%. Six non-cytotoxic lead compounds, ranging from
active to highly active, belonging to new antichlamydial chemotypes were found in the
process.
There is an urgent need of promising hit and lead molecules for antimicrobial drug
discovery. The results presented herein suggest the described dibenzocyclooctadiene
lignans from the fruits of Schisandra chinensis to be active against C. pneumoniae. Since
these  compounds  proved  to  be  active,  non-cytotoxic  to  the  host  cells  and  selective  in
antichlamydial action, they present promising candidates for further lead development.
Considering the lack of validated targets in antichlamydial drug discovery, ligand-based
methods,  such  as  the  successful  LBVS approach  described  in  this  work,  are  suitable  for
future projects in the field of natural product drug discovery.
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13
“Natural products are privileged compounds in antibiotic discovery.
They are genetically encoded products of natural selection.
They have been molded by evolution to interact with biological targets;
as such they represent proven and outstanding leads for drug discovery.”
-  Gerard D. Wright, PhD, 2014
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1. INTRODUCTION
As a common pathogen in humans, Chlamydia pneumoniae (or Chlamydophila
pneumoniae) has a remarkable role in the global disease burden (Wyrick, 2000; Roulis et
al., 2013). The impact of the acute infection as respiratory diseases can be more clearly seen
than that of the chronic latent forms of the infection.
Insufficient response to the first line antibiotics and the risk of persistence remain major
challenges in treatment of chlamydial infections (Ekman et al., 1993; Hammerschlag &
Kohlhoff, 2012; Kohlhoff & Hammerschlag, 2015). Despite the in vitro susceptibility of
C. pneumoniae to  several  antibiotics,  treatment  failures  are  a  matter  of  concern.  The
antibiotics currently in use against C. pneumoniae do not eradicate the chronic form of the
disease (Gieffers et al., 2004). In addition, in clinical care rapid diagnostic methods for
identification of pathogens causing an infection allow prescribing more targeted antibiotics
for selective therapy (Caliendo et al., 2013). Pathogen-specific compounds can be used
rationally against the infection causing pathogen, which will delay the development of
resistant strains, and leave the body’s natural microbiota unharmed.
Nature is a rich source of potential lead compounds. Many compounds obtained from the
plant kingdom are in drug market as such, or serve as a basis for semi- or total synthesis of
drugs. Plant derived compounds together with antibiotics and biological drugs, i.e.
compounds of biogenic origin or natural products, constitute majority of the drug market
and continue to provide lead compounds that have entered clinical trials (Newman & Gregg,
2007; Newman & Gregg 2012; Harvey et al., 2015). The original technical reasons why the
pharmaceutical industry abandoned plant derived natural products are outdated.
Development in the fields of mass spectrometry and nuclear magnetic resonance, compound
purification and identification, genomics and metabolomics, as well as the diversity of
screening libraries has brought natural products back as an even more fruitful source for
lead compounds than ever before (Clardy & Walsh 2004; Lewis, 2012; Wright, 2014;
Harvey et al., 2015). Natural products and natural product inspired compounds form a
15
diverse chemical space for computational and biological methods for screening of new hit
and lead molecules.
Virtual screening (VS) can be used to facilitate high-throughput screening (HTS) of large
compound libraries. The screening process generally begins with either an already known
target protein, or a reference set of ligands which bind to the target and cause the wanted
biological activity (Dobi et al., 2014). Ligand-based approaches are especially useful when
the target is unknown.
In this thesis, the discovery of new antichlamydial compounds is based on phenotypic
assays on chlamydial infections, with an aim towards selective antichlamydial agents. With
the help of ligand-based virtual screening (LBVS) combined with in vitro experiments, a
privileged antichlamydial chemical space can be defined. Focusing on the hit and lead
compounds’ properties, such as non-toxicity and lead-likeness, we aim to provide promising
lead candidates for further drug development.
16
2. REVIEW OF THE LITERATURE
2.1 Chlamydia pneumoniae
Chlamydia pneumoniae is the most common Chlamydia in humans and virtually everyone
is infected in a lifetime (Grayston, 2000). The seroepidemiological studies have shown an
antibody prevalence of 50–70%, the figures increasing by age of the studied population
(Grayston, 1992; Benitez et al., 2012). The most commonly infected are the children at
school age. Within the children the infection manifests as mild upper respiratory tract
symptoms, whereas adults typically suffer from a more severe long-lasting pneumonia. As
a common respiratory pathogen, the participation of C. pneumoniae in chronic pulmonary
inflammations has strong evidence (Grayston, 1992; Hahn et al., 2002; Hahn et al., 2012).
Acute complications of C. pneumoniae infection include some severe although rare
diseases, such as reactive arthritis (Gérard et al., 2000). Yet, the chronic consequences are
more significant considering the whole population.
There are many globally significant diseases that have been associated with chronic
C. pneumoniae infections:  chronic obstructive pulmonary disease (COPD), asthma,
atherosclerosis, reactive arthritis and lung cancer (Gérard et al., 2000; Zhan et al., 2011;
Hahn et al., 2012; Roulis et al., 2013). Four of five patients with chronic bronchitis, as also
patients with adult or juvenile asthma, express signs of a persistent Chlamydia infection.
Acute Chlamydia infections are sensitive to quinolones, tetracyclines and macrolide
antibiotics (Kohlhoff & Hammerschlag, 2015). Despite the good response, there is a
remarkable risk of the infection relapsing and turning into chronic. Chronic Chlamydia
infection in turn cannot be cured with antibiotics (Kern et al., 2009). Thus, the question is
how we can affect chronic Chlamydia infection and the diseases with pathogenesis in which
it plays a key role. Obviously, there is an urgent need for new biologically active compounds
with antichlamydial activity.
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2.1.1 History and epidemiology
Chlamydia pneumoniae was first thought to be a virus, most likely due to its intracellular
life  style  and  small  size.  Early  reports  from  the  1930’s  and  1940’s  mention  a  pathogen
causing atypical pneumonias. It was noted that the earlier described meningopneumonitis
virus is a psittacosis-like virus (Eaton et al., 1941). This finding was one step closer to the
reality, since psittacosis is an atypical pneumonia caused by Chlamydia psittaci, the third
species of the genus Chlamydophila,  which  was  known  to  consist  of  only  two  species,
Chlamydia trachomatis and Chlamydia psittaci, by 1960’s. The first clinical isolate of the
pathogen was thought to be a new Chlamydia psittaci strain  called  TWAR,  and  it  was
obtained in 1965 from a conjunctivitis of a Taiwanese child, and named TW-183 (Grayston
et al., 1986). From this finding it took over two decades until the strain “TWAR” was
suggested to be an independent species, Chlamydia pneumoniae (Grayston et al., 1989).
Consequently, the species C. pneumoniae is a relatively recently identified pathogen and
the epidemiological studies made ever since indicate the remarkable role of this newcomer
in the clinic.
C. pneumoniae is a common cause of community-acquired pneumonia (CAP) accounting
for  about  10%  of  all  the  cases  (Hahn et al., 2002). The most (70%) of acute human
C. pneumoniae respiratory tract infections are asymptomatic or only mildly symptomatic
but a smaller part of them (30%) cause more severe respiratory illnesses including
community-acquired pneumonia (CAP) which is the leading cause of hospitalizations and
death among the patients over 65 years in developed countries (Vila-Corcoles et al., 2009).
CAP cases in this population have increased as a consequence of an overall increase in the
elderly and the patients at risk. Seroepidemiological surveys show, that in most populations,
antibody prevalence is low in children below the age of five, rising during school years and
then persisting throughout adulthood (Grayston, 1992; Hahn et al., 2002). Prevalence of a
chlamydial antibody, measured with micro-immunofluorescence (MIF) assay, increases up
to 40% to 50% between ages 5 and 20 rising only gradually thereafter (Grayston, 1992).
This indicates that most primary infections occur in children and young adults.
C. pneumoniae is  distributed  worldwide,  with  an  estimate  of  up  to  50%  of  adults
18
seropositive in all geographic locations examined (Hahn et al., 2002). C. pneumoniae
causes outbreaks of pneumonia in all age groups in close-quarters living environments, such
as military installations, prisons and universities (Miyashita et al., 2005; Coon et al., 2011;
Fajardo et al., 2015).
2.1.2 Developmental cycle
Chlamydiales is a genus of small gram-negative bacteria that are classified as a separate
taxonomic group due to their intracellular reproduction cycle (Figure 1). The characteristic
developmental cycle is remarkably conserved throughout the whole Phylum Chlamydiae.
Chlamydia pneumoniae infection is initiated by attachment of the infective extracellular
forms, elementary bodies (EBs) to the host cell surface (Wolf et al., 2000). Several different
surface proteins located in the outer membrane of EBs have been suggested as chlamydial
adhesins. These serve as ligands in receptor-mediated endocytosis. Chlamydia bacteria use
glycosaminoglycans (GAGs) as receptors for cell attachment (Wupperman et al., 2001).
GAGs are the polysaccharide chains of proteoglycans, found ubiquitously on the surface of
eukaryotic cells. Many pathogens use GAGs as receptors for cell attachment. For
Chlamydia pneumoniae the  cellular  receptor  is  heparan  sulfate-like  GAG.  An  important
virulence factor in certain intracellular gram-negative bacteria, type 3 secretion system
(T3SS), is also essential for the infectivity of Chlamydia spp (Ouellette et al., 2005; Fields
et al., 2003). T3SS is a protein appendage, also called injectisome, which allows direct
effector protein injection into the host cell cytosol, creating an environment which favors
bacterial growth and survival. During the entry-phase the chlamydial EBs internalize into
the host cell within the first two hours of infection. The chlamydial phagosomal vesicle,
called inclusion is not detected by the host cell, and it thereby escapes the lysosomal fusion.
During the following 1–8 hours the EBs differentiate into the intracellular metabolically
active  forms,  reticulate  bodies  (RBs).  The  RBs  replicate  inside  the  inclusion  by  binary
fission. Chlamydia uses  the  host  cellular  nutrients  for  its  own  metabolism,  for  example
cholesterol (Carabeo et al., 2003). Acute infection lasts for 48–72 hours and during that
period  of  time  the  chlamydial  RBs  multiplicate  and  transform  into  EBs,  which  are  then
released from the cell to infect new cells. Occasionally, atypical growth of RBs is detected,
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and these developmental forms, called aberrant bodies (ABs), are considered as a hallmark
of the persistent Chlamydia infection (Kern et al., 2009). Persistence can be described as a
stage of infection where viable but culture-negative, yet nucleic acid-positive organisms
reside in the cells (Beatty et al., 1994; Bin et al., 2000).
2.1.3 Chlamydial envelope structure
Chlamydiae have a gram-negative special envelope structure which consists of the inner
membrane and a lipopolysaccharide (LPS)-containing outer membrane (Tamura et al.,
1971; Aistleitner et al., 2015). The known protein constituents include LPS, 60 kDa heat
shock protein (HSP-60), 12 kDa protein and 40 kDa major outer membrane protein
(MOMP).  In the envelope structure of Chlamydia there are also some non-proteinaceous
components such as LPS, other glycolipids, phospholipids and fatty acids.
Figure 1. Life-cycle of Chlamydia pneumoniae
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Lipopolysaccharide (LPS), a typical membrane molecule of gram-negative bacteria, is the
main antigenic component of Chlamydiae (Nurminen et al., 1983). Chlamydial LPS (cLPS)
has been shown to contain the characteristic constituents of bacterial LPSs (Nurminen et
al.,  1985).  On  the  other  hand  cLPS  is  less  immunogenic  than  other  bacterial  LPS
(Kalayoglu, et al., 2000). One interesting feature of cLPS is that cLPS antigen has been
shown to accumulate in the plasma membrane of infected cells (Karimi et al., 1989). This
is followed by decreased membrane fluidities which the authors suggested to have possible
consequences on endocytic processes, lysosome-endosome fusion and complement-
mediated cytolysis. The described action of Chlamydia could be seen as the bacteria’s way
of hiding from the host cell’s immunity system, as the most intriguing proposal.
It was noted a long time before the order Chlamydiales’s taxonomic identification that the
reticulate bodies of the meningo-pneumonitis are less rigid, highly labile forms that do not
survive outside the host cell (Tamura & Manire, 1967). Since then it has been shown in
several studies that the envelope structure varies between the different life cycle forms of
Chlamydiae (Hatch, 1996). The overall assessment is that the envelope of metabolically
inactive elementary bodies (EBs) consists of densely cross-linked cysteine-rich proteins
(CRPs) which might respond to the osmotic stability of EBs. An opposing observation has
been made of the reticulate bodies (RBs), which are metabolically active, but osmotically
stable. RBs lack the disulfide cross-linked envelope proteins. To further indicate the
difference, it is also seen in the formation of CRPs, such as 12 kDa CRP and a large 60 kDa
CRP doublet that are present only in EBs but absent in dividing RBs (Hatch et al., 1984). It
has been proposed, that this structural difference in CRPs might be the reason for the
metabolic and osmotic divergences of EB’s and RB’s (Hackstadt et al., 1986). The earlier
studies indicated that Chlamydia lacks the peptidoglycan (PG) in their cell wall, and it was
suggested  that  major  outer  membrane  protein  (MOMP)  may  substitute  to  the  PG  as  a
structural component (Garrett et al., 1974; Newhall & Jones, 1983; Hatch et al., 1984). Later
it  has  been  shown that  there  is  functional  PG in  the  cell  wall  of Chlamydia trachomatis
(Liechti et al., 2014).
In addition to the CRPs mentioned above, there are other disulfide cross-linked envelope
proteins. Probably the most interesting structural protein, MOMP, consisting of disulfide
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linked amino acid chains, is the main component of Chlamydia’s cell wall. It is similar in
molecular weight and composition between the different chlamydial species although, there
are some differences (Campbell et al., 1990; Perez Melgosa et al., 1991). It has been
suggested, that C. pneumoniae MOMP would be less immunogenic and antigenically
complex than those of the other chlamydial species. The main function of this protein is in
maintaining cell wall rigidity. Similar to the other envelope proteins, the consistence of
MOMP varies between the different life cycle forms of the bacteria. The MOMP of EBs is
tightly cross-linked with disulfide bridges and it is insoluble in sodium dodecyl-sulfate
(SDS) a detergent used to solubilize chlamydial inner membrane proteins in the absence of
mercaptoethanol (Hatch et al.,  1981).  The  solubility  of  MOMP  in  the  presence  of
mercaptoethanol and insolubility in the absence of emphasizes the importance of disulfide
bridges to the maintenance of the structural stability of the protein. Mercaptoethanol was
used  as  a  reducing  agent,  and  reduction  of  the  disulfide  residues  is  assumed  to  cause
envelope proteins tertiary conformation to denaturize.
2.1.4 Diagnostics and clinical challenges
In diagnosing pneumonia, specifying the causative pathogen organism is neither feasible
nor cost-efficient in all patients, and resources for full diagnostic work-up are spared for
moderate and high risk patients and nosocomial infections (Lim et al., 2009; Woodhead et
al., 2011). The first line treatment in pneumonia are beta-lactam antibiotics which are not
selective to Chlamydia or Mycoplasma.  If  the  symptoms  persist  or  there  are Chlamydia
pneumoniae or Mycoplasma pneumoniae epidemias, then an antibiotic selective to these
will be added to the treatment. This procedure is preferred and used as a national healthcare
guideline in Finland, because there is lack of unambiguous research evidence about benefits
in taking the presence of C. pneumoniae or M. pneumoniae into consideration when
choosing the antibiotic in the first line treatment (Käypä hoito -suositus, 2015:
www.kaypahoito.fi).
Acute infection of C. pneumoniae can be diagnosed by serology measuring the level of
C. pneumoniae antibodies. This can be done with microimmunofluorescence test (MIF)
using elementary bodies (EBs) as antigens and measuring separately IgG and IgM levels
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(Wang, 1999). Recently, a Food and Drug Administration (FDA)-approved molecular
diagnostic test for respiratory pathogens, including C. pneumoniae, has become available
(FDA, 2012: www.fda.gov). In the future this will enable standardized testing and targeted
treatment of respiratory infections.
The first line treatment of chlamydial infection is azithromycin or doxycycline (Kohlhoff
& Hammerschlag, 2015). One problem in treatment of pneumonia is that the penicillin
antibiotics used to treat the most common causative agent of CAP, Streptococcus
pneumoniae, are shown to trigger persistence in C. pneumoniae (Matsumoto & Manire,
1970; Schoborg, 2011). C. pneumoniae instead, is not very often diagnosed for the above
mentioned reasons. In addition to that, the persistent form at the moment is very difficult to
diagnose. A widely accepted criteria for serological diagnostics of the persistent form does
not exist and diagnosing is based on the symptoms (Boman & Hammerschlag, 2002; Bunk
et al.,  2010).  A  major  problem  in  diagnosing  is  that  serological  tests  are  not  able  to
discriminate between past and persistent infections. There are no antibiotics to treat the
persistent form, but there are some studies that show that in the treatment of acute infection
the dose and the course of antibiotic treatment should be sufficient, because subinhibitory
concentrations of antibiotics are shown to trigger persistence (Gieffers et al., 2004) and
resistance in vitro by serial  passage (Kutlin et al., 2005). However, the role of antibiotic
resistance or persistent infections in treatment failures is not clear (Kohlhoff &
Hammerschlag, 2015). Instead, the mass distribution of azithromycin has led to incidence
of azithromycin-resistant fecal Escherichia coli (Seidman et al., 2014) and azithromycin-
resistant Streptococcus pneumoniae carriage in young children (Coles et al., 2013).
C. pneumoniae and cardiovascular events are shown to have a connection (Saikku et al.,
1988; Player et al., 2014). Strongest evidence is gained from the connection to
atherosclerosis, and it suggests that it might be a risk factor in the onset and/or development
of  the disease.  In respect  to  these findings of  the relation of  chronic C. pneumoniae with
atherosclerosis, there are several papers that study the Chlamydia selective antibiotics in the
treatment of coronary diseases and show no evidence of the connection (O’Connor et al.,
2003; Andraws et al., 2005; Cannon et al., 2005). Due to the numerous inconsistent
findings, a meta-analysis of randomized controlled trials suggested that there is no benefit
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of antibiotic therapy in reducing mortality or cardiovascular events in patients with coronary
artery diseases (Andraws et al., 2005). The lack of significance in these studies is stated to
reverse the theory of connection of the chronic infection with atherosclerosis. The problem
with this statement is the fact that these antibiotics do not have effect on the chronic
infection, so the lack of their effect to atherosclerosis cannot disprove the connection.
2.1.5 Antichlamydial treatment
Antibiotics in the treatment of acute Chlamydia pneumoniae infection are macrolides and
fluoroquinolones, of which more specific are ketolides and respiratory fluoroquinolones,
respectively (Kohlhoff & Hammerschlag, 2015). The latter have a good
intracellular/extracellular ratio and thus are suitable for treatment of intracellular pathogens
(Tulkens, 1991; Rakita, 1998).
Macrolide antibiotics attach to the bacterial ribosome 50S subunit inhibiting their protein
synthesis at translocation phase. In this class of compounds azithromycin is the most
capable of transferring into tissues and also accumulating into white blood cells.
Azithromycin is the gold standard in the treatment of C. pneumoniae.  In  addition  to  the
protein synthesis inhibiting class of antibiotics tetracycline based compounds are also used
for this purpose but they do not accumulate in cells and may be present at insufficient
concentrations.
Fluoroquinolones inhibit bacterial DNA gyrase which in turn inhibits duplication of
bacterial DNA. In comparison to the bacteriostatic macrolides, fluoroquinolones are
bactericidal in their nature. Fluoroquinolones have also a good ability of penetrating into
tissues.
The antibiotics whose mechanism of action is based on the weakening of bacterial cell wall,
penicillins in general, do not have a remarkable effect on Chlamydias because of them
lacking peptidoglycan (PG) in their cell walls (Garrett et al., 1974; Newhall & Jones, 1983).
Inhibition of the cross binding of PG chains is the mechanism of action of penicillins.
However, Chlamydias have some susceptibility to anti-PG antibiotics, which exhibits a
phenomenon known as “chlamydial anomaly”. Later this anomaly has been reversed, as it
has  been  shown  that  there  is  functional  PG  in  the  cell  wall  of Chlamydia trachomatis
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(Liechti et al., 2014). It also was already shown earlier that Chlamydias have penicillin-
binding proteins, and they are in that way somewhat sensitive to drugs that inhibit PG
synthesis (Barbour et al., 1982).
Chronic Chlamydia is resistant to antibiotics, and some antibiotics can be used to induce a
persistent infection at subinhibitory concentrations. The first-choice antibiotics in the
treatment, macrolides, tetracyclines, rifampin, and quinolones, are shown to induce
persistence (Gieffers et al., 2004). A number of other antibiotics which have no specific
effect on Chlamydia are also used to induce persistence. Penicillin G is widely used in this
meaning, although it’s mechanism of induction remains unclear (Matsumoto & Manire,
1970; Schoborg, 2011). It has been suggested that it might be due to host cell gene silencing
during a chlamydial infection (Peters et al., 2005).
2.1.6 Antichlamydial drug research: therapies in clinical trials
There are several new antichlamydial agents in early clinical development. A novel DNA
gyrase inhibitior AZD0914, developed by Astra Zeneca, has showed promising activity
against Chlamydia pneumoniae and Chlamydia trachomatis in vitro (Kohlhoff et al., 2014).
The activities against both pathogens were comparable to levofloxacin and 16-fold less than
the gold standard, azithromycin, based on MIC90 values. The authors declared that the
results gained by the in vitro protocol used in the study has a validated correlation with
clinical outcomes. Activities obtained measuring MBC values (minimal bactericidal value,
vs. MCC, minimal chlamydiacidic value) were remarkably lower than that of azithromycin,
indicating higher recovery rates of the isolates after the treatment. The role of AZD0914 in
the treatment of chlamydial infections depends on the outcome of clinical studies assessing
microbiological efficacy.
Two new quinolones, nemonoxacin and delafloxacin are introduced for the treatment of
C. pneumoniae and C. trachomatis. Nemonoxacin (TG873870) is a novel broad spectrum
non-fluorinated quinolone, which has shown antichlamydial activity against the both
species (Chotikanatis et al.,  2014).  It  differs  from  fluoroquinolones  only  in  that  it  lacks
fluorine atom in R6 position. The in vitro activity of nemonoxacin against C. trachomatis
was 2-fold lower than that of azithromycin, but against C. pneumoniae it was comparable
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with that of levofloxacin, doxycycline, and azithromycin. However, as the authors noted, in
vitro activity does not necessarily predict microbiologic efficacy in vivo against
C. pneumoniae. Considering that the fluorine atom in the fluoroquinolones’ position R6 has
over ten-fold increase to the DNA gyrase inhibiting effect, and can decrease MIC-values
100-fold, the clinical relevance remains to be elucidated by in vivo experiments.
Delafloxacin, a novel fluoroquinolone lacking a basic substituent in position 7, has shown
low MIC values against gram-positive and gram-negative bacteria, including atypical
pathogens such as C. pneumoniae (van Bambeke, 2015). It is recently evaluated in Phase
III trials and qualified for the treatment of community-acquired bacterial pneumonia (CAP),
due to its high activity on pneumococci and atypical pathogens.
A new fluoroketolide antibiotic, solithromycin (CEM-101), has recently entered clinical
trials (Golparian et al., 2012). The MIC90 values against both C. pneumoniae and
C. trachomatis were only two-fold less than that of azithromycin (Roblin et al., 2010). Other
new ketolides, cethromycin and telithromycin were considered attractive additions to
antibacterial tool kit for mild-to-moderate CAP (Georgopapadakou, 2014). The first
ketolide to be approved, Sanofi-Aventis’ telithromycin (RU 66647, HMR 3647, Ketek®),
was withdrawn from clinical development due to controversial FDA approval concerning
rare, irreversible hepatotoxicity that included deaths. Cethromycin (ABT-773), originally
developed by Abbott, completed phase III clinical trials and filed New Drug Application,
but it was denied by the FDA in 2009. Enanta’s modithromycin (EDP-420), is currently in
Phase  II  in  Japan.  All  of  these  above  listed  ketolides  have  activity  against  CAP causing
atypical pathogens, including C. pneumoniae.
Despite the excellent activity in treatment of chlamydial infections, the use of rifamycins,
rifampicin and a newer derivative rifalazil, in that indication is discouraged due to them
developing resistance relatively fast (Kutlin et al., 2005).
Sitafloxacin (DU-6859a), a new-generation oral fluoroquinolone with broad range in vitro
activity against gram-positive and -negative bacteria, as well as against atypical bacterial
pathogens, was approved in Japan in 2008 (Ghebremedhin, 2012). In Caucasian population
its use is currently limited due to the potential for ultraviolet A phototoxicity.
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In addition to investigational antimicrobials that have modifications to already existing
antibiotics, there are studies concerning antichlamydial potential of drugs for other than
antimicrobial indications. There is data about calcium channel blockers, such as verapamil
in clinical use inhibiting C. trachomatis (Shainkin-Kestenbaum et al., 1989), but opposite
observations with L-type calcium channel blockers improving the growth of C. pneumoniae
(Azenabor & Chaudhry, 2003).
2.1.7 Plant phenolic compounds’ and extracts’ antichlamydial effect
The health beneficial effects of polyphenolic compounds of plant origin are widely reported.
There are several in vitro and in vivo studies that show the antichlamydial activity of
multiple plant-derived phenols in acute infections (Vuorela et al., 2001; Vuorela et al.,
2004; Törmäkangas et al., 2005; Alvesalo et al., 2006b; Salin et al., 2010; Salin et al.,
2011a; 2011b). In a study, a susceptible cell line, HL (human line, lung epithelial cells) cells
were infected with Chlamydia pneumoniae clinical isolate K7 (Kajaani 7) (Alvesalo,
2006b). Antichlamydial activity was seen in various compound groups of plant derived
phenolic compounds. These substances belong to the chemical groups of flavones,
flavonols, coumarins and gallates. Inhibition of the growth of C. pneumoniae clinical isolate
K7 was 100% with some of the compounds. There were remarkable structure–activity
variances between the same groups of compounds. With flavones and flavonols it was
suggested that compounds with sugar moieties were generally less active against
C. pneumoniae than those with only aglycone present. In contrast to most antibiotics that
act only against metabolically active forms of bacteria, several phenolic compounds in the
study, especially rhamnetin, were active also against the inactive chlamydial elementary
bodies (EBs). It was also shown, that some of the natural phenolic compounds had the
ability to accumulate inside the host cells or cell membranes and caused inhibition even
when they were present only prior to infection. Coadministration of natural phenolic
compounds, quercetin, luteolin, rhamnetin and octyl gallate, with calcium modulators,
isradipine, verapamil and thapsigargin, resulted in potentiation of the phenolic compounds
(Salin et al., 2011a). The calcium modulators alone did not show any inhibitory effect on
the growth of C. pneumoniae. The plant phenolic compounds were also assayed together
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with doxycycline, and they did not potentiate the effect of this chlamydiacidic antibiotic in
vitro. Another study showed that phenolic compounds resveratrol and quercetin improved
the antichlamydial effect of clarithromycin and ofloxacin (Rizzo et al., 2014). Also in this
study it was found that resveratrol and quercetin alone inhibit intracellular C. pneumoniae
growth.
Highly active compounds against C. pneumoniae are also found from other chemical groups
different from flavonoids. An in vitro study with C. pneumoniae clinical isolate CV-6 (CV,
cardiovascular) and CWL-029 showed a natural lupane-class triterpene betulin and its
derivatives to be highly active inhibitors of C. pneumoniae (Salin et al., 2010). One
synthetic derivative, betulin dioxime, had a minimal inhibitory concentration (MIC) of
1 μM against CWL-029 and was active with nanomolar concentrations.
In addition to the above mentioned in vitro studies there is in vivo data showing the
antichlamydial activity of plant polyphenolic compounds.  An in vivo study with a mouse
model presented the effects of two flavonoid compounds, quercetin and luteolin, and an
alkyl gallate, octyl gallate, on acute Chlamydia pneumoniae infection (Törmäkangas et al.,
2005). Luteolin and quercetin were found to be effective in both suppressing the lung
inflammatory response and decreasing the chlamydial load in lung tissue. The luteolin
treatment also lowered the levels of C. pneumoniae-specific antibodies in serum. Octyl
gallate did not display any significant effect on the course of infection. The authors
speculated the best inhibitory activity of luteolin to be due to its better bioavailability of the
free aglucon form compared with the other two compounds. Another mouse model of
C. pneumoniae infection with isolates K7 and CWL-029 assayed the antichlamydial effect
of corn mint (Mentha arvensis, L.) extract. The extract was able to diminish the
inflammatory parameters relate to C. pneumoniae infection and genome equivalents (Salin
et al., 2011b). The main phenolic components in the extract linarin and rosmarinic acid
inhibited the growth of strain K7 by over 60% at a concentration of 100 μM. Also tea
polyphenol product was tested in vitro against both C. pneumoniae strains AR-39 and
AC-43,  as  well  as C. trachomatis strains D/UW-3/Cx and L2/434/Bu (Yamazaki et al.,
2003). The product showed complete inhibition of both pathogens, and authors believed
this to encourage the topical use of tea polyphenols in treatment of chlamydial infections.
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2.1.8 Other experimental compounds
Cathelicidin peptides which are natural defense compounds in mammalian leukocytes could
be considered as lead compounds for antichlamydial use (Donati et al., 2005). This theory
was challenged by a finding of a chlamydial plasmid-encoded virulence factor Pgp3, which
was shown to neutralize the antichlamydial activity of human cathelicidin LL-37 (Hou et
al., 2015). Cationic antimicrobial peptides (AMPs) are shown to interact with negatively
charged microbial membranes, thus permeabilizing the membrane phospholipid bilayer,
resulting in lysis and the death of microbes (Hancock et al., 2002). Several plant peptides
showed activity against Chlamydia trachomatis (Balogh et al., 2014). However, the exact
mechanisms of action of AMPs are poorly understood.
A ligand binding to mannose receptor, M6P-PAA, was active against both C. trachomatis
and Chlamydia pneumoniae with 72% decrease in infectivity compared to infected control
to the latter pathogen (Kuo et al., 2007). Inhibition was shown in vivo in a mouse model.
Since chlamydial mannose oligosaccharide is shown to mediate attachment and infectivity
of Chlamydia trachomatis and Chlamydia pneumoniae in vitro, the mannose receptor
inhibiting ligands affect the attachment and entry to the host cell. The authors suggested
M6P-PAA for topical use, for example in mouthwashes for preventing pneumonia.
Other non-antibiotic compounds with antichlamydial activity are heparin, (Wupperman et
al., 2001), some COX-2 inhibitors (Yan et al., 2008), statins slightly reduced C. pneumonia
growth (Kothe et al., 2000) and rapamycin (immunosuppressant compound) (Yan et al.,
2010). Contradictory data has been obtained with corticosteroids. One study shows that
corticosteroids increase C. pneumoniae infection (Malinverni et al., 1995), but the other
study demonstrates that a steroid receptor antagonist mifepristone inhibits the growth of
C. pneumoniae (Yamaguchi et al., 2008).
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2.2 Antimicrobial drug discovery
2.2.1 Current status
Discovery of penicillin in 1928 started the golden era of antimicrobial drug discovery, and
during that time nearly all of the antimicrobials used nowadays were invented. Since then
the discovery of new antimicrobials has ceased and resistance to the existing antibiotics
increases all the time. According to many sources including researchers and health care
authorities we have entered a post-antibiotic era meaning that the era of antibiotics may
have come to an end (WHO, 2011: www.who.int; Viens, 2015).  According to the World
Health Organization (WHO) (WHO, 2014: www.who.int), ‘the problem is so serious that it
threatens the achievements of modern medicine. A postantibiotic era — in which common
infections and minor injuries can kill — is a very real possibility for the 21st century’.
According to some estimations bringing a new drug to market takes approximately 10–15
years (antibiotics, reviewed in Fowler, 2014) and costs 1.8 billion dollars (Paul et al., 2010)
(See Figure 2. for schematic presentation of drug discovery process). These estimations vary
intensively depending on the therapeutic  area.  Also what  comes to costs  the figures vary
depending on the time frame of discovery process, company in question and whether cash
or capitalized costs are compared (Chit et al., 2015). Since the drug discovery process gets
more expensive as it continues, it is reasonable to eliminate the possible risks in as early
phase  as  possible.  There  is  always  a  high  risk  for  failure  in  what  comes  to  absorption,
distribution, metabolism, excretion and toxicity (ADME-Tox) properties of the drug
candidate. In addition to that antimicrobials, when they finally reach the market, are
normally used only for a small period of time, in comparison to regularly used drugs, such
as for example antihypertensive drugs or drugs to treat diabetes (Wright, 2014). Thus
antimicrobials  do  not  generate  as  much  revenue  for  the  company  as  the  regularly  used
medicines (Fowler et al., 2014; Wright, 2014). Taken into account the relatively poor
risk/benefit-ratio, it is obvious that from the pharmaceutical industry point of view
discovery of antimicrobials does not always seem like the most promising investment.
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However,  antimicrobial  resistance  is  a  well  acknowledged  global  threat,  which  has  been
compared to catastrophes such as major flooding, terrorist attacks and pandemic outbreaks
by health authorities (Viens, 2015; Cabinet Office UK, 2015: www.gov.uk). WHO has
announced that urgent actions are necessary if the effectiveness of antibiotics is to be
ensured in the future (WHO, 2011: www.who.int). It is said that the disaster of antimicrobial
resistance is not inevitable so now is at last time to take action (Fowler, 2014; Viens, 2015).
Figure 2. Drug discovery pipeline
2.2.2 Strategies
In early drug discovery the lead finding strategies can be roughly divided into two
categories: target based methods and cell based or phenotypic assays (Macarrón &
Hertzberg,  2011).  In  the  first  approach  an  isolated  target  molecule  is  screened  against  a
compound library for finding a molecule that interacts with the target. By the early 2000s
the disappointments with the success rates of molecular-based hit discovery campaigns
made the industry to change the course back towards cell-based high throughput screening
(HTS). The whole cell based in vitro environment proved naturally better in mimicking the
in vivo physiology than the isolated target molecules. In some cases experiments with
isolated targets give the best answers, but this depends on the hypothesis. To discover a new
antimicrobial  drug  there  are  as  well  several  strategies  and  their  variations  (Lipinski  &
Hopkins, 2004). These attempts begin with either a known target or a promising positive
result from a phenotypic experiment. In the latter approach the screening protocol begins
similarly  as  with  the  target  screening,  but  in  these  experiments  also  drug  candidate
compounds are included. In an antimicrobial screen the experimental set up consists of
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infected control, uninfected control and drug treated control. Usually HTS methods are
applied in order to find lead molecules that interact with the target (Keserü & Makara,
2009). The libraries are either commercial or in-house libraries consisting of hundreds to
thousands or even tens of thousands of compounds. These are then screened in multiwell-
plate system. Despite the huge number of candidate compounds, compared to the virtually
infinite number of molecules in the chemical space, even a few million molecules in a HTS
library make little difference in sampling. Also the possible drug–protein interaction
varieties are immense (Lipinsky & Hopkins, 2004). The drug can bind to a receptor, a
different subpopulation of a receptor, ion channel or an enzyme, the protein can be located
on the cell membrane, or be intracellular and the binding can have different affinities and
selectivities. Another strategy, a developed version of HTS is high content screening (HCS),
which has proven successful in screening of antichlamydial compounds (Hanski & Vuorela,
2014; Marwaha et al., 2014).
2.2.2.1 Ligand-based virtual screening
Despite the huge financial investments and expectations in HTS in yielding new promising
lead molecules, the overall result has been somewhat disappointing (Keserü & Makara,
2009). Taken into account the infinite possibilities of the chemical space and biological
space and their interactions, without validated screening protocols and tools finding new
drug candidates may seem more hopeless than finding a needle in a haystack.  Virtual
screening (VS) offers a very ecological and time saving approach to facilitate HTS. VS tools
are proposed for avoiding the synthesis of trivial analogues and instead search through
chemical space for topologically similar entities using known active compounds or
pharmacophores as references (Bleicher et al., 2003). Combining computational methods
to HTS has enabled a move from purely random-based testing to high content screening
(HCS) and focused libraries. VS also diminishes costs and time when the vast compound
library can be tested virtually, which allows reducing costly and laborious in vitro
experiments. VS methods can be either target-driven or ligand-based. Especially when the
target is unknown ligand-based virtual screening (LBVS) approaches offer a solution to hit
and ligand screening. LBVS are typically based on a collection of molecules known to bind
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to a set of related targets (Dobi et al., 2014). The reference set of ligands is used to perform
similarity searches against one or more databases of a selected library. The amount of
reference ligands can vary from a single molecule to multiple molecules, but the careful
selection of the reference set is highly important, since it defines the chemical space for
similarity search (Walters et al., 2003). One key element in performing these types of
searches is novelty. Using a similarity metric that is too uniform tends to identify molecules
that are close analogues of the known ligands used to perform the search.  In an ideal case
the similarity metric identifies molecules that are functionally equivalent to the reference
set, but chemically distinct enough to bring additional novelty to the search.
2.2.2.2 (Q)SAR studies based on similarity searches
Designing the optimal drug requires the best physicochemical and pharmacodynamics
features from a candidate molecule. Because the number of all the possible analogues of a
molecule and their combinations is infinite, structure–activity relationship (SAR) or
quantitative SAR (QSAR) studies can help in guiding the synthesis. Another application is
in defining a chemical space where to find active lead candidates. These studies aim to
identify the physicochemical properties of a compound that are responsible for the
biological activity and/or other desired features. One way of determining structure–activity
correlations is to use data matrices derived from molecule similarity calculations (Good et
al., 1993). The computational similarity searches are based on the idea that called similarity
principle (Martin et al., 2002), which states that similar molecules are likely to have similar
physicochemical properties and therefore might have similar biological activity. The
similarity metrics can use 2D or 3D structure representation of molecules, structural
fingerprints and molecular descriptors in the calculations, and the data is compared using a
similarity index. This depends on the method in use, and there are several different
similarity measures. Most methods use simple distance measures such as Euclidean distance
and association coefficients such as Tanimoto coefficient or Tanimoto index.
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2.2.2.3 ChemGPS-NP as a tool for screening
In a review in Nature 2004 Lipinski & Hopkins compared chemical space with the
cosmological universe: “Chemical space can be viewed as being analogous to the
cosmological universe in its vastness, with chemical compounds populating space instead
of stars” (Lipinski & Hopkins, 2004). This analogy was well accepted by the scientific
community,  as  it  describes  very  well  the  challenge  for  drug  discovery  to  find  the
biologically active compounds in the chemical space. That challenge is to identify those
regions that are likely to contain biologically active compounds, the biologically relevant
chemical  space.  For  example  the  compounds  that  bind  to  same  target  classes,  such  as
G protein-coupled receptors (GPCRs), are clustered together in discrete regions of chemical
space. The regions can be defined by particular chemical descriptors. For chemical
compounds one can calculate a range of properties, such as charge, number of atoms,
number of rotatable bonds etc. (Stockwell, 2004). These properties, called descriptors, can
be calculated using commercially available software. A chemography tool, ChemGPS
(chemical global positioning system), is created of data set which consists of 423 structures
selected for a balanced chemical space, largely based on the Lipinski’s rule of five (Oprea
& Gottfries, 2001). It combines predefined rules and objects as dimensions to provide a
global drugspace map. These rules include general properties of a chemical compound, such
as size, lipophilicity and hydrogen bond capacity. The coordinates of the drugspace map are
extracted by principal component analysis (PCA) from a list of molecular descriptors that
evaluate the rules on a selected set of molecules. PCA is a mathematical method, widely
used in drug discovery to transform a multidimensional descriptor space into a more
manageable low dimensional space (Larsson et al., 2007). The possibly correlated variables
of  a  data  set  are  compressed into a  smaller  number linearly uncorrelated variables  called
principal components (PCs). Using the chemography tool PCA-score prediction is used to
project new molecules on the map, to explore the chemical space which these particular
compounds occupy. The comparison to the reference set is described numerically as
Euclidean distances. It has been noted, that natural products (NPs) tend more often to fall
outside the ChemGPS defined chemical space (Larsson et al., 2005). The reason is thought
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to  be  that  in  comparison  to  the  druglike  synthetic  molecules  for  which  the  system  was
initially designed, NPs are very different in terms of structure and chemical properties.
Larsson and coworkers proposed that ChemGPS as such is not suitable for complex and
atypical  NPs,  and  the  expansion  of  ChemGPS was  made  into  ChemGPS-NP,  where  NP
stands for natural products (Larsson et al., 2005; Larsson et al., 2007; Rosén et al., 2009).
2.2.3 Hit identification
Since HTS hasn’t produced as much new drugs as anticipated, researchers have elaborated
on the methodology to high content screening (HCS) and more targeted smaller libraries.
Also quality of the screen has been addressed and the factors in a particular screen that affect
finding a hit, such assay quality parameters like Z’-factor, signal/noise or signal/background
ratio, IC50 and statistical significance (Walters et al., 2003). There are also several other
issues in the screen that should be taken into consideration in hit or lead discovery. Careful
compound selection which take into account physical properties, ADME properties and
drug-likeness, or lead-likeness, are things to pay attention in designing the screen. It is said
that in compound selection no factor has a larger role than the compounds used for the
screen.  In addressing the issues of the compounds selection according to their properties
computational approaches can be of great value. These include methods such as protein–
ligand docking, similarity searching, pharmacophore searches and property profiling. There
has been debate about including the requirements for ADME properties in the early drug
discovery, and some researchers suggests that, it might be premature to use predictive
ADME at the hit screening stage, because the compounds will usually undergo significant
changes during the lead-optimization process. Some analyses of drug-discovery programs
have pointed out that drug candidates are typically larger and more lipophilic than the initial
lead (Hann et al., 2001; Oprea, 2002). This is speculated to be a result of a tendency of
medicinal synthetic chemists to more often add functional groups to the lead candidates,
rather than eliminating them. On the basis of these observations, it has been concluded that
it might be beneficial to select such compounds in the early screens that are predicted to be
soluble and orally bioavailable. Not only optimizing the screening protocol, it is essential
to choose the correct strategy for finding appropriate leads (Bleicher et al., 2003). Among
35
other things this includes the questions whether a target or ligand-based approach would be
suitable (See chapter 2.2.2: Strategies).
2.2.4 Hit-to-lead validation
When  the  natural  source,  for  example  an  extract,  has  proven  biological  activity,  it  is
essential to define the compound or compounds responsible for that activity. This kind of
molecule  can  act  as  a  hit  or  lead  compound.  In  the  early  drug  discovery  process  it  is
important to define lead molecules from hit molecules, and it is not enough for a successful
lead molecule to show biological activity. As the cost of drug discovery process increases
the further it gets, possible failures must be identified and eliminated as early as possible
(Bleicher et al., 2003). To distinguish the drug-like and nondrug-like molecules from each
other there are some requirements for a hit molecule that fit the description lead-likeness or
drug-likeness (Ajay et al., 1998). The most famous rule of a thumb to look for drug-likeness
is the Lipinski’s rule of five. It states that “historically 90% of orally absorbed drugs had
fewer than five hydrogen bond donors, less than ten hydrogen bond acceptors, molecular
masses of less than 500 daltons and logP values (a measure of lipophilicity) of less than
five” (Lipinski et al., 1997; Lipinski et al., 2012). This rule is created to estimate solubility
and permeability of a drug in discovery and development. The aqueous solubility, in terms
of hydrophilicity, is crucial for a compound to get in contact with the absorption site, for
example  gut  wall.  On  the  other  hand,  if  the  drug  is  too  hydrophilic,  it  is  not  able  of
penetrating biological barriers, like the gut wall or cell membranes. The hydrophilicity–
hydrophobicity balance is often described as logP value. In addition to solubility and
absorption, a successful lead candidate needs to possess adequate bioactivity, appropriate
physicochemical properties to enable formulation development, reasonable metabolic
stability and appropriate safety and efficacy in humans (Pritchard et al., 2003). Nowadays
in the drug discovery process information about the toxicity of a compound is required in a
very early phase. The overall cell toxicity is tested in vitro, and gives a very good exclusion
criterion for a compound. This will save effort and expenses in the further process. For
predicting the optimal properties of a lead compound and finding it from vast chemical
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libraries the computational methods offer time and resources saving processes to the
discovery.
2.2.5 Natural products
Nature is a rich and mainly unexplored source of biologically active compounds. Many
active substances in drugs sold in the pharmacy nowadays are originally isolated from a
natural source, such as morphine, cocaine, digitalis, quinine, nicotine, muscarine, paclitaxel
(taxol) and tubocurarine. Compounds that are used as such or serve as a basis for semi- or
total synthesis from plant kingdom, together with antibiotics produced by microbes and
biological drugs, comprise majority of the drug market (Newman & Gregg, 2007; Newman
& Gregg,  2012).  Thus,  it  can  be  said  that  nature  has  served,  and  will  serve,  as  the  most
abundant source of drugs, and most of it still remains unexplored (Wright, 2014). Natural
products (NPs) are developed by evolution and they have very often been selected for
properties that allow them to cross biological barriers, such as bacterial cell wall. Nature
has taught us invaluable lessons in the logic of biosynthesis for developing new drugs, as
well as properties of different functional groups, which helps in synthesizing new molecules
(Clardy  &  Walsh,  2004).  During  the  recent  20  years  there  has  been  a  trend  within  the
pharmaceutical industry to downscale efforts in NP research, with the present knowledge
and technology this could be reconsidered. The problems with NPs that made the companies
withdraw from the field are outdated (Clardy & Walsh, 2004; Lewis 2012; Wright, 2014).
These problems included challenges with identifying the active components from natural
product extracts and difficulty in synthesis. With current technological advances especially
in the field of mass spectrometry and nuclear magnetic resonance, compound purification
and identification are brought to a wholly new level. Going back to explore new chemical
entities  and therapeutically relevant  chemical  diversity in  the nature seems to offer  great
potential for drug discovery industry.
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2.3 Schisandra lignans
Schisandra chinensis (Turczaninow) Baillon, “Wu Wei Zi” in Mandarin, is a liana native to
the forests of Eastern Asia (Hancke et al., 1999). It produces bright red fruits spherical in
shape and growing in clusters. S. chinensis is  known  for  its  use  in  Traditional  Chinese
Medicine (TCM) — and overall in Far East, ethnopharmacologically — and is used to treat
several disorders of the reproductive, respiratory, nervous, and digestive systems (Hancke
et al., 1999; Panossian & Wikman, 2008). Traditionally in Russia, the fruits of S. chinensis
are considered a stimulant and adaptogen. Nowadays the herb is used in dietary supplements
mainly as an adaptogen.
Schisandra lignans have various different synonyms in the literature (Opletal et al., 2004).
The constituents of S. chinensis berries  can  be  divided  into  four  classes:
dibenzocyclooctadiene lignans, which represent the dominant secondary metabolite
component in the berries, monoterpenes, sesquiterpenes and other compounds of various
structures (Opletal et al., 2004). The lignans are predominantly dibenzocyclooctadiene in
structure, which also are responsible for the majority of the declared biological activities of
the berries (Lu & Chen, 2009). In the group of dibenzocyclooctadiene lignans the dominant
compounds are schisandrin and schisandrin B, which are also the most studied ones. In this
thesis some of the major dibenzocyclooctadiene lignans are presented (Table 1.).
Dibenzocyclooctadiene lignans from plants in the genus Schisandra, i.e. Schisandra
lignans, are shown to have various pharmacological activities, such as neuro-, cyto- and
hepatoprotective, as well as anti-cancer and anti-inflammatory effects (Guo et al., 2008;
Stacchiotti et al., 2009; Lee et al., 2012; Liu et al., 2012; Lv et al., 2015). These activities
were obtained with either schisandrin or schisandrin B at 5 and 6.25 μM concentrations
respectively in cell models, and with schisandrin B at 1–30 mg/kg in animal models, as the
lowest concentrations to give statistically significant results. Schisandra lignans are also
shown to have anti-viral activities, including anti-HIV activity (Chen et al., 1997; Yang et
al., 2010), inhibition of HSV-2 and adenovirus (Song et al., 2013), and inhibition of
Epstein–Barr virus early antigen activation (Chen et al., 2002). The lowest EC50 values
obtained in these studies against HIV-1 were 0.005 μg/ml for gomisin G (Chen et al., 1997)
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and 1.4 μg/ml for new lignans identified in the same study (Yang et al., 2010). The lowest
EC50 values for HSV-2 and adenovirus were 5.85 μg/ml and 22.10 μg/ml respectively,
gained with new lignans identified in the same study (Song et al., 2013). The effect of
Schisandra lignans on respiratory pathogens is not known, but Schisandra chinensis
(Turcz.) Baill. is used in TCM for several indications, and one of them is treatment of
chronic cough (Chinese pharmacopoeia, 2010). In a clinical study results have suggested
that a tincture of Schisandra fruit has alleviating effect on the symptoms of pneumonia
(Pavluschenko et al., 1981, reviewed in Panossian & Wikman, 2008). In the study the
causative agent of pneumonia was not determined. Also other clinical studies made in the
former USSR with Schisandra tinctures show a reduced prevalence of influenza in study
subjects treated with Schisandra tincture (Panossian & Wikman, 2008). In addition there
are modern in vitro and in vivo studies that show Schisandra chinensis’ protecting effect in
alveolar inflammation. Schisandra chinensis water extract prevented airway inflammation
both in vitro and in vivo (Bae et al., 2012). In human alveolar epithelial cells Schisandra
Table 1. Schisandra lignans presented in this work; core structure and functional groups
Schisandra lignan R1 R2 R3 R4 R5 R6 R7
Schisandrin OCH3 OCH3 OCH3 OCH3 H OH CH3
Schisandrin A OCH3 OCH3 OCH3 OCH3 H OH CH3
Schisandrin B -O-CH2-O- OCH3 OCH3 H OH CH3
Schisandrin C -O-CH2-O- -O-CH2-O- H H CH3
Schisandrol B -O-CH2-O- OCH3 OCH3 H OH CH3
Schisantherin A -O-CH2-O- OCH3 OCH3 O-C-O-Bz CH3 OH
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extracts inhibited cytokine mixture induced NO production and reduced IL-8 and MCP-1
secretions. The extracts also suppressed neutrophil and macrophage infiltrations of lung
tissues and increased IL-6 and TNF-? levels in bronchoalveolar lavage fluid in LPS-treated
BALB/c mice. A pure compound, schisantherin A, was shown to alleviate acute respiratory
distress syndrome through downregulating NF-?B and MAPKs signaling pathways in vivo
in a mouse model at 10 mg/kg concentration (Zhou et al., 2014).
2.3.1 Schisandra lignans’ antioxidative activity
Schisandra lignans are widely studied for their antioxidant properties, which is considered
one major mechanism responsible for the cytoprotective effects (Liu et al., 1982; Opletal et
al., 2004; Guo et al., 2008; Zeng et al., 2012) (Table 2.). The antioxidant or reducing
properties of the lignans are also shown to mediate the anti-inflammatory responses. For
example, in a study schisandrin B displayed anti-inflammatory activities which were due to
alteration of cellular redox status leading to inhibition of nuclear factor (erythroid-derived
2) 2 -like 2 (Nrf2) and NF-?? (Checker et al., 2012). Schisandrin B suppressed I???
degradation and nuclear translocation of NF-?? in activated lymphocytes. In the same study
schisandrin B was shown to inhibit mitogen-induced phosphorylation of c-Raf, MEK, ERK,
JNK and p38. Schisandrin B-mediated activation of Nrf2 was proposed to suppress NF-??,
which is a redox sensitive pathway. Nrf2 induces production of antioxidative enzymes, as
NAD(P)H:quinone oxidoreductase, glutathione S-transferase, HO-1, glutathione
peroxidase, glutamate cysteine ligase, and peroxiredoxin 1. These factors are known to
diminish reactive oxygen species (ROS). Thus it can be concluded that Nrf2 activation of
schisandrin B leads to anti-inflammatory responses that are mediated by ROS. It was also
noted that schisandrin B inhibited anti-CD3/CD28 mAb-induced secretion of IL-2, IL-4,
IL-6 and IFN-? by T-cells. In two other studies schisandrin B enhanced apoptosis through
activation of a redox-sensitive Nrf2 pathway (Chiu et al., 2009; Chiu et al., 2011). The
antioxidative activity of schisandrin B was further confirmed in a study which showed
schisandrin B to inhibit the production of ROS and NADPH oxidase activity in microglia
(Zeng et al., 2012). NADPH oxidase-dependent superoxide O2 and ROS formation were
LPS induced.
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Table 2. Schisandra lignans’ and Chlamydia pneumoniae’s effects on selected host
cellular targets
Host cell target Schisandra lignan /
Chlamydia: Effect
on host cells*
Schisandra lignan Reference: Schisandra
/ C. pneumoniae
Intracellular
A
PO
PT
O
SI
S
Bcl-2 protein
family
- / ± schisandrin B Lv et al., 2015 / Fischer
et al., 2004; Schöier et
al., 2006
Caspase-3
pathway
+ / - schisandrin B Wu et al., 2004 /
Airenne et al., 2002
Cytochrome c - / - schisandrin B Chiu et al., 2009 /
Airenne et al., 2002
O
X
ID
A
TI
V
E
ST
A
TU
S GSH + / - schisandrin B Ip & Ko, 1996 /
Azenabor et al., 2006
NADPH
oxidase
- / + schisandrin B Checker et al., 2012 /
Mouithys-Mickalad et
al., 2004
ROS ± / + schisandrin B Checker et al., 2012;
Zeng et al., 2012 /
Mouithys-Mickalad et
al., 2004
O
TH
ER
SI
G
N
A
LL
IN
G
A
G
EN
TS
Ca2+ - / + schisandrin A,
schisantherin A
Fu et al., 2008 /
Wang et al., 2010
ERK1/2 - / + schisandrin B & C,
schisantherin A
Oh et al., 2010 /
Jiang et al., 2008
Heat shock
proteins
Hsp25 + ; Hsp70 ± ;
Hsp72 + / Hsp60 +
schisandrin B Chiu & Ko, 2004;
Wu et al., 2004 /
Hirono et al., 2003
JNK - / + schisantherin A,
schisandrin B & C
Oh et al., 2010 /
Jiang et al., 2008
MEK - / + schisandrin B Guo et al., 2008 /
Jiang et al., 2008
NF-?B - / + schisandrin A & B,
schisantherin A
Guo et al., 2008 /
Wahl et al., 2001
p38 MAPK - / + schisandrin A & B,
schisantherin A
Guo et al., 2008 /
Jiang et al., 2008
TRAF-6 - / + schisandrin B Zeng et al., 2012 /
Jiang et al., 2008
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Membrane
proteins
EGFR - / + schisandrin B Waiwut et al., 2011 /
Mölleken et al., 2013
Toll-like receptor 2
& 4
- / + schisandrin B Zeng et al., 2012 /
Jiang et al., 2008
Secreted factors
COX2 - / + schisandrin,
schisandrin B
Guo et al., 2008
/Mouithys-Mickalad et
al., 2004
iNOS - / - schisandrin B Zeng et al., 2012 /
Shimada et al., 2009
NO - / - schisandrin,
schisandrin B,
schisantherin A
Guo et al., 2008 /
Shimada et al., 2009
IFN-? - / + schisandrin B Checker et al., 2012 /
Buss et al., 2010
IL-1 - / + schisandrin B,
schisantherin A
Zeng et al., 2012 /
Kaukoranta-Tolvanen et
al., 1996
IL-6 - / + schisantherin A Zeng et al., 2012 /
Heinemann et al., 1996
IL-8 (CXCL8) + / + schisandrin,
schisandrol B
Lin et al., 2011 /
Al-Bannawi et al., 2011
Matrix
metalloproteinases
2 & 9
- / + schisandrin B Lee et al., 2012 /
Kol et al., 1998
PGE2 - / + schisandrin,
schisandrin B
Guo et al., 2008 /
Rödel et al., 2004
TNF-? - / + schisandrin B,
schisantherin A,
Zeng et al., 2012 /
Jiang et al., 2008
Vascular
endothelial growth
factor (VEGF)
- / + schisandrin B Lv et al., 2015 /
Wang et al., 2010
*inductor effect indicated with + and inhibitory effect indicated with -. Opposing effects
are indicated with grey background.
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2.3.2 Immunity, inflammation, LPS-induced mechanisms
Schisandra lignans are shown to be able of suppressing the inflammatory responses induced
by bacterial lipopolysaccharide, LPS (Guo et al., 2008; Oh et al., 2010) (Table 2.).
Schisandrin was found to inhibit in vitro LPS-stimulated production of nitric oxide (NO),
prostaglandin E2 (PGE2), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase
(iNOS), which was shown to result from the inhibition of nuclear factor-kappaB (NF-??)
reporter gene expression and activation of c-Jun N-terminal kinase JNK and p38 mitogen-
activated protein kinases (MAPKs) (Guo et al., 2008). In another study a group of different
Schisandra lignans, Gomisin J, N and schisandrin C, were shown to reduce LPS-induced
NO production and expression of pro-inflammatory cytokines by blockage of p38 activated
MAPK, ERK1/2 and JNK phosphorylation (Oh et al., 2010). They also decreased mRNA
levels  of  IL-1  and  IL-6  and  TNF-? in  LPS-activated  cells.  Schisandrin  C  reduced
phosphorylated ERK1/2 to the level of untreated control. Gomisin N did not affect p38
MAPK or ERK1/2, but LPS-induced phosphorylation of JNK was reduced by gomisin N
pretreatment, and also by gomisin J and schisandrin C pretreatment. One report that studied
the anti-neuroinflammatory effects of schisandrin B showed that this schisandrin inhibited
LPS-induced neuronal cell death and LPS-induced production of NO, PGE2 and TNF-?,
and downregulated expression of IL-6 and IL1beta mRNA in LPS treated microglia (Zeng
et al. 2012). Schisandrin B significantly reversed the LPS-induced phosphorylation of
IKK??? and I?? and reduced the total I?? expression level in a concentration dependent
manner. Pretreatment with schisandrin B significantly decreased NO and PGE2 production
by inhibiting iNOS and COX-2 protein expression.  Schisandrin B inhibited the interaction
of toll-like receptor 4 (TLR4) and TLR2 with Toll adapter proteins MyD88, IRAK-1 and
TRAF-6, which was proposed to indicate that schisandrin B may inhibit the IKK???-I??-
NF-?? inflammatory signaling pathway via selective antagonism of TLR4.
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3. AIMS OF THE STUDY
The study of this thesis is focused on whole-cell assays on chlamydial infections, careful
evaluation of the physicochemical properties of the lead candidates and attempts towards
more narrow-spectrum antichlamydial agents as elements for successful lead generation.
The specific aims of this thesis were:
1. To study the antichlamydial activity of peppermint tea water extracts. To optimize
further the acute cell culture model for detection of Chlamydia pneumoniae
infection in vitro, which can be used for screening new drug candidates in drug
discovery process. (I)
2. To investigate the antichlamydial effect of Schisandra chinensis water–methanol
extract and compare the effect with isolated Schisandra lignans. (II)
3. To study the Schisandra lignans’ effect on the host cell–Chlamydia interaction and
on the life-cycle of Chlamydia pneumoniae. (III)
4. To evaluate the promising antichlamydial compounds’ suitability as successful lead
compounds. (III–IV)
5. To study the structure–activity relationships of a variety of antichlamydial
compounds. Build a training set for ChemGPS-NP for screening of antichlamydial
hit compounds from a natural product library. To validate the in silico results with
in vitro antichlamydial assays. (IV)
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4. MATERIALS AND METHODS
4.1 Plant material and preparation of the extracts (I–II)
Commercially  available  peppermint  herbal  teas  (n  =  27)  in  the  form of  crude  herb  were
purchased from food markets, health shops and retail pharmacies, originating from Egypt,
Estonia, EU, Finland, Germany, Latvia, Poland, The Netherlands, UK and USA (I). The
infusions from the herbal teas were made according to manufacturer’s instructions with
distilled  water,  filtered  and  centrifuged  at  4000  rpm  for  15  min.  at  20  °C.  The  total
polyphenol content and quantification of individual polyphenols was done by HPLC-UV-
MS/MS analyses.
The powdered berries of Schisandra chinensis (Turcz.)  Baill.  were  purchased  from
Loitsukeller, Estonia (II). Their identity and schisandrin content were investigated by
macroscopic and microscopic identification, as well as thin-layer chromatography (TLC)
and high-performance liquid chromatography (HPLC) tests according to European
Pharmacopoeia guidelines (European Pharmacopoeia, 2010).
The 80% aqueous methanol extract was prepared from 5.0 g of finely powdered S. chinensis
berries by sonicating the mixture for 10 min at room temperature following that the extract
was vacuum-filtered and evaporated to dryness using a rotary evaporator. The residue was
dried under N2-flow and frozen at -20 °C overnight. The frozen extract was lyophilized and
dissolved in dimethyl sulfoxide (DMSO) to a concentration of 100 mg/ml for the in vitro
experiments. This stock solution was used for making dilutions of 10, 25, 50, 100 and
250 ?g/ml final concentrations in growth medium the concentration of DMSO not
exceeding 0.25%.
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4.2 Pure compounds (II–IV)
Dibenzocyclooctadiene lignans ? 98% (HPLC) (Fine Tech Industries, London, UK) were
dissolved to dimethyl sulphoxide (DMSO) as 20 mM stock solutions. L-ascorbic acid at
250 μM concentration, l-dithiothreitol and n-acetyl-l-cysteine at 10 mM concentration
(solid pure compounds obtained from Sigma–Aldrich, Germany) were dissolved in
deionized sterile water prior to experiments (III). Antichlamydial virtual hits that were
tested in vitro were obtained from Screen-Well® natural product library version 7.1 (Enzo
Life Sciences), as 2 mg/ml stock solutions in DMSO, and diluted in cell culture medium for
in vitro antichlamydial assays (IV). More detailed information about the test compounds is
listed in Table 3 and Table 4. As control antibiotics for chlamydial growth inhibition was
used 12 nM rifampicin (II) and 20 nM azithromycin (III, IV).
Table 3. Test compounds used in publications II and III
Compound Purpose Publication CAS nr.
Schisandrin Schisandra lignan II, III 7432-28-2
Schisandrin A Schisandra lignan III 61281-38-7
Schisandrin B Schisandra lignan II, III 61281-37-6
Schisandrin C Schisandra lignan III 61301-33-5
Schisandrol B Schisandra lignan III 58546-54-6
Schisantherin A Schisandra lignan III 58546-56-8
L-ascorbic acid reducing agent III 50-81-7
L-DTT reducing agent III 16096-97-2
N-acetyl-l-cysteine reducing agent III 616-91-1
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Table 4. Virtual hits used in publication IV
Compound CAS nr.
6-Acetamido-6-deoxy-
castanospermine
134100-29-1
Aphidicolin 38966-21-1
Apigenin-7-O-glucoside 520-36-5
(?)-Asarinin 133-05-1
Baccatin III 27548-93-2
Betulin 473-98-3
Caffeic acid phenethyl ester 104594-70-9
Caryophylleneoxide 1139-30-6
Catharanthine base 2468-21-5
Cevadine 62-59-9
Chartreusin 6377-18-0
Chrysine 480-40-0
Cinobufagin 470-37-1
Convolvamine HCl 500-56-1
Coumesterol 479-13-0
Cycloheximide 66-81-9
Deguelin 522-17-8
Dehydrokawain 15345-89-8
Digitoxin 71-63-6
Dihydroergocristine
mesylate 24730-10-7
Dipterocarpol 471-69-2
Epicathecin 490-46-0
Eriocitrin 13463-28-0
Flavanomarein 577-38-8
Gossypol 303-45-7
Compound CAS nr.
Graveoline 485-61-0
Harmaline HCl 304-21-2
Hesperidine 520-26-3
Honokiol 35354-74-6
7-Hydroxyflavone 6665-86-7
Hypocrellin A 77029-83-5
Indirubin 479-41-4
Isoquercitrine 21637-25-2
Jervine 469-59-0
Laudanosoline HBr 485-33-6
Leucomisine 17946-87-1
Lupinine 545-47-1
Manool 596-85-0
Mycophenolic acid 24280-93-1
Nalidixic acid 389-08-2
Nonactin 6833-84-7
Norleaginine 16502-01-5
Oleanolic acid 508-02-1
Oridonin 16964-56-0
Osthole 484-12-8
Peganole 36101-54-9
Pimaricin 7681-93-8
Podocarpic acid 5947-49-9
Prostaglandin B1 13345-51-2
Radicicol 12772-57-5
Remerine HCl 17669-16-8
Syrosingopine 84-36-6
4.3 Host cell lines and chlamydial strains
Human  epithelial  HL  cells  (Human  line,  respiratory  origin,)  are  a  sensitive  cell  line  for
propagation of Chlamydia pneumoniae (Kuo & Grayston, 1990) and were used as host cells
for C. pneumoniae strains K7 (Kajaani 7) clinical isolate (Ekman et al., 1993) and CV6
cardiovascular strain recovered from atherosclerotic lesions (Gieffers et al., 1998). HL cells
were grown in Roswell Park Memorial Institute medium-1640 (RPMI-1640, Lonza,
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Verviers, Belgium) supplemented with 2?mM l-glutamine (Lonza), 7.5% fetal bovine serum
(FBS) (Gibco, NY, US) and 20??g/ml gentamicin (Sigma, MO, USA) at 37?°C, 5% CO2 and
95% humidity to confluence in cell culture flasks. C. pneumoniae stocks were stored in
0.2?m sucrose (Sigma), 0.02?m sodium phosphate (Sigma–Aldrich, Germany) (pH 7.4) and
??mM glutamic acid (Sigma) sucrose-phosphate-glutamic acid (SPG) buffer at -80?°C until
use.
HeLa-229 cells (CCL-2.1; ATCC, Manassas, VA, USA) for the infections with Chlamydia
trachomatis serovar L2 (VR-902B; ATCC), were grown in RPMI-1640 supplemented with
10% FBS, 20 mM HEPES (Sigma) (pH 8.0), 8 μg/ml gentamicin, 1 μg/ml amphotericin B
(Sigma) and 2 mM l-glutamine at 37 °C, 5% CO2 and 95% humidity. C. trachomatis stocks
were stored as above (as C. pneumoniae).
4.4 Infections
HL cells were grown to confluence in cell culture flasks, washed with phosphate-buffered
saline (PBS) (Lonza, Verviers, Belgium) and detached with trypsin (Lonza) 0.25% in PBS.
The cell suspension was seeded into 24-well plates (Greiner, Germany) with coverslips
(VWR international) at 4 × 105 cells per well and incubating for 24?h at 37 °C, 5% CO2 and
95% humidity. The growth medium was removed and cell monolayers were inoculated with
a suspension of Chlamydia pneumoniae EBs suspended in cell culture medium
supplemented with 0.5??g/ml cycloheximide (Sigma, China), a mammalian cell 80 S
ribosome inhibitor, with the multiplicity of infection (MOI) 0.2. The plates with inoculated
cells were centrifuged at 550?g for 1?h and incubated at 37 °C for 1?h to allow the EBs to
internalize into the host cells. Medium supplemented with 1??g/ml cycloheximide
containing the samples or controls was added. Non-treated infected cells, infected cells
treated with 0.01??g/ml rifampicin and non-infected cells served as controls. In each well
the concentration of DMSO was adjusted to 0.25%. Plates were incubated for 70 h at 37 °C,
5% CO2 and 95% humidity. Seventy-two hours post infection the infection was terminated
by washing the wells with PBS fixing the cells with methanol. The coverslips were removed
from the wells and dried in room temperature. The Chlamydia inclusions were labeled with
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Pathfinder® Chlamydia Culture Confirmation System (Bio-Rad Laboratories, Berkeley,
CA, USA) according to manufacturer’s protocol. The inclusion counts were determined
with fluorescent microscope at × 200 magnification.
The infections done with Chlamydia trachomatis were carried out in a similar manner as
the C. pneumoniae infections with the following exceptions. Confluent HeLa-229 cells
were infected with C. trachomatis serovar L2 diluted in Hank’s balanced salt solution
(HBSS) at multiplicity of infection 0.3. After 1?h incubation at 37?°C, HBSS was replaced
with growth medium including test compounds or solvent alone (1% DMSO). Cell cultures
were fixed at 24?h, immunostained with Pathfinder® and examined under fluorescent
microscope.
4.5 Evaluation of the target:  phase of infection
4.5.1 Infectious progeny production
HL cells were seeded into 24-well plates with and without coverslips, infected and treated
with  the  samples  as  described  above.  After  72?h  infection  (first  passage)  the  number  of
infectious progeny was determined by washing the wells with PBS and replacing the sample
containing medium with fresh medium without the samples. The wells with coverslips were
fixed and stained to calculate the inclusions (first passage). The infected cell layers were
then disrupted and cell lysates from the wells without coverslips were used to infect fresh
HL cell monolayers. After another 72?h infection (second passage) the cells were fixed and
stained to determine the amount of infectious progeny.
4.5.2 Elementary body infectivity
To evaluate direct effects on chlamydial elementary bodies, Chlamydia pneumoniae stocks
were diluted in the RPMI medium supplemented with 0.5??g/ml cycloheximide to yield a
400 000 IFU/ml suspension and the studied compounds were added in aliquots of the EB
suspension. The suspension was incubated at +4 °C for 1 h and was then used to infect HL
cells as described above.
49
4.6 Intracellular ROS detection
The level of intracellular reactive oxygen species (ROS) were measured with modifications
to an earlier presented protocol (Wang & Joseph, 1999). HL cells were seeded into 96-well
plates to 60?000 cells per well, incubated overnight to confluence and loaded with 20??M
2’7’-dichlorodihydrofluorescein diacetate (DCFH-DA) (Sigma, MO, USA) for 30?min at
37 °C. The excess label was removed from the wells and washed once with Hank’s balanced
salt solution (HBSS) prior to the exposure of the cells to the samples for 1?h at 37?°C. RFUs
(relative fluorescent units) were measured at 503/523 (ex/em) with VarioskanFlash plate
reader (Thermo Fischer Scientific, Vantaa, Finland). 1?mM hydrogen peroxide (Aldrich,
Germany) and N-acetylcysteine served as positive and negative controls. To determine a
possible interference between the samples and the dye, a similar experiment was performed
with only samples and DCFH-DA (Sigma, MO, USA) (no cells). The potential effects of
dye de-esterification or efflux were excluded with a 2’7’-dichlorofluorescein diacetate
(DCF-DA) assay.
4.7 Host cell viability assays
Extract- and compound-treated HL and HeLa cell viabilities were confirmed by resazurin
assay.  Seeding of  the HL-cells  into a  96-wellplate  to  a  density of  5 × 103 (growing) and
6 × 104 cells (confluent) per well followed by overnight incubation at 37 °C. One column
was left without cells and served as a background. Triton X (Sigma–Aldrich) (II) and 50
μM usnic acid (Aldrich, Switzerland) (I, IV) were used as positive controls. The following
day the samples and controls were added onto cell monolayers. DMSO concentration was
adjusted to 0.25% in every well. After that the plate was incubated at 37 °C in 5% CO2, the
exposure corresponding the acute infection period. To measure the amount of metabolically
active cells, a profluorescent dye, resazurin in PBS, was added into the wells. The plate was
incubated for 2 h at 37 °C and fluorescence was measured with VarioskanFlash plate reader
at 570/590 nm (ex/em).
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4.8 Selectivity assays: turbidity and fluorescence measurements
The growth inhibition of metabolically active bacteria, other than Chlamydia, by the
Schisandra extract and the lignans were assayed with turbidity and fluorescence
measurements of the bacterial suspension (protocol adapted from Sandberg et al., 2009).
Gram-negative bacteria; Enterobacter aerogenes (ATCC; 13048), Escherichia coli (ATCC;
25922), Proteus mirabilis (ATCC; 43071), Pseudomonas aeruginosa (ATCC; 27853) and
gram-positive bacteria; Bacillus subtilis (ATCC; 6633), Staphylococcus aureus (ATCC;
25923) and Staphylococcus epidermis (FOMK;  in-house  strain)  were  grown  on
Bacteriological agar Type A (VWR international) (III). Gram-positive bacteria
Streptococcus pneumoniae (DSM 11867, DSMX Collections) and Streptococcus pyogenes
(ATCC; 12351) were grown in Todd–Hewitt broth (BD, France) (II). Gram-negative
Klebsiella pneumoniae (HAMBI culture collection; 1332) was grown in nutrient broth
(Sigma–Aldrich, Spain) (II). The bacterial culture was inoculated to 10?ml of nutrient broth
and grown overnight at 37?°C in a shaker at 100?rpm. A 500 × dilution of the inoculum in
the broth was seeded into a 96-well plate. The samples were added at 50??M concentration
and non-treated cultures, cultures treated with either 12?nM (0.01? g/ml) rifampicin or
20??g/ml ampicillin were used as control samples. Wells with nutrient broth alone served
as background. The amount of DMSO was adjusted to 0.25% in each well. Starting point
turbidity was measured as light absorbance at 590?nm with VarioSkan Flash plate reader.
The plates were incubated for 24?h on a shaker at 37?°C, 100?rpm. The change in turbidity
was measured at 590?nm. Resazurin at 20??M in PBS was added and incubated for 5?min at
37?°C, on a shaker in darkness and the fluorescence was measured with VarioSkan flash
plate reader at 560/590?nm (ex/em).
4.9 Structure–activity relationship studies with ChemGPS-NP
4.9.1 Constructing of the reference set of compounds
Reference antichlamydial compounds were selected according to literature by the following
criteria: nature derived structurally diverse compounds shown to completely inhibit the
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growth of a same strain and isolate of Chlamydia pneumoniae at 50 μM concentration. The
following compounds fulfilled the criteria with 100% growth inhibition of C. pneumoniae
clinical isolate K7 (Kajaani 7): acacetin, apigenin, coumarin 106, 7-diethylamino-3-
thenoylcoumarin, dodecyl gallate, luteolin, methoxy sporalen, methyl gallate, morin,
myricetin, octyl gallate, propyl gallate, rhamnetin, rotenone (Alvesalo et al., 2006b);
biochanin A (Hanski et al., 2014), schisandrin A, schisandrin B, schisandrin C,
schisantherin A (original publication III). In the paper IV linear notations of the molecules
were used, canonical SMILES (Simplified molecular-input line-entry system) codes.
SMILES annotations for these 19 reference compounds were obtained from web based
databases ChemSpider (www.chemspider.com) and PubChem (www.pubchem.net).
4.9.2 Chemical space analysis
The SMILES codes were exported to ChemGPS-NP (Larsson et al., 2007; Rosén et al.,
2009) which is freely available online: http://www.chemgps.bmc.uu.se/. This platform takes
into account size, shape, lipophilicity, polarity, polarizability, flexibility, rigidity and
hydrogen bonding capacity in forming an eight-dimensional chemical space. ChemGPS-NP
space map is constructed of t-scores from principal component analysis (PCA) (Larsson et
al., 2007). In paper IV the four first principal components (PC1–PC4) were used because
they are the most significant PCs and explain 77% of the variance. PC1 consist of
descriptors for size, shape and polarizability, PC2 for aromatic- and conjugation-related
properties, PC3 for lipophilicity, polarity and H-bond capacity and PC4 describes flexibility
and rigidity.
The target library, Screen-Well® natural product libarary version 7.1 Cat. No. BML-2865-
0500 (Enzo Life Sciences, Inc., Enzo Biochem, Inc., Farmingdale, New York), that was
screened against the 19 antichlamydial reference compounds consisted of 502 compounds
covering alkaloids, coumarins, flavones, isoflavones, macrolides, peptolides, terpenoids and
synthetic derivatives of previous compound groups. The chemical space analysis was made
from 2D descriptors (total of 35) that describe physical-chemical properties of the
compounds and are calculated from canonical SMILES. All salts, hydration information,
and counter-ions were excluded from the SMILES annotation, and differences in
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stereochemistry ignored, since ChemGPS-NP only uses 2D descriptors. Mapping of the
chemical space was done in a two-dimensional or a tri-dimensional space, using Grapher
for Mac (version 10.4). For the in vitro assays the pure compounds that were in the library
as 2 mg/ml in dimethylsulfoxide (DMSO) stock solutions were diluted in cell culture
medium and used at 50 μM final concentration in the well.
4.9.3 Ligand-based virtual screening
Euclidean distances (EDs) were computed between the reference compounds (19) and the
natural products library compounds (502). EDs were calculated between points P = (p1,
p2,...,p4) and Q = (q1, q2,...,q4) in Euclidean 4-dimensional space provided by the
ChemGPS-NP coordinates:
𝐸𝐷 = ඥ(𝑝ଵ − 𝑞ଵ)ଶ + (𝑝ଶ − 𝑞ଶ)ଶ + (𝑝ଷ − 𝑞ଷ)ଶ + (𝑝ସ − 𝑞ସ)ଶ
For graphical visualization of EDs a heat map was constructed using Gnuplot (version 4.5).
The virtual hits were selected by choosing the three closest compounds to the reference set
of compounds. Compounds that appeared repeatedly were chosen only once. One alreadly
known antichlamydial compound, betulin (Salin et al., 2010), was excluded.
4.10 Statistical analyses
Data is expressed as the ± SEM, and analyses are performed by either the Student’s t-test
or  ANOVA  using  SPSS  Statistics  21.0  software. P-values  below  0.05  are  regarded  as
statistically significant and indicated in the figures with a sign *. Accordingly, P-values
below 0.01 are indicated with ** and P-values below 0.001 with *** (I–IV). SPSS Statistics
21.0 was used to obtain the best curve fit for constructing the dose–response curves for the
estimations of IC50 values.
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5. RESULTS
5.1 Inhibition of the growth of Chlamydia by the studied extracts
and compounds (I–III)
Seven commercial peppermint tea water extracts inhibited the growth of Chlamydia
pneumoniae clinical  respiratory  isolate  K7  at  250.0  ?g/ml  (n  =  3)  (I).  The  tea  samples
inhibited the chlamydial growth in the range of 20.7% to 69.5%.
The aqueous methanol extract of Schisandra chinensis berries  was  administered  to  the
Chlamydia infected host cells and the respiratory pathogen cultures (II). The final
concentrations of the extract were 10, 25, 50, 100 and 250 μg/ml in each experiment. The
extract inhibited all the chlamydial species and strains in a dose-dependent manner. The
MIC values against C. pneumoniae strains  CV6  and  K7  were  <  100  μg/ml,  whereas
C. trachomatis was less susceptible with the MIC value exceeding 250 μg/ml.
There were remarkable differences in the antichlamydial activities of Schisandra lignans
(Table 5.). However, there is no consistent pattern in functionalities that could contribute to
the increased activity. In all of the experiments schisandrin B inhibited chlamydial growth
remarkably more than schisandrin with an over two-fold lower IC50 value against
C. pneumoniae. Schisandrin had virtually no activity on the growth of C. trachomatis. All
of the six Schisandra lignans inhibited the growth of C. pneumoniae and C. trachomatis in
a dose-dependent manner with three of them having a MIC value of 50 μM against
C. pneumoniae, and one of them, schisandrin C, a MIC value of 25 μM.
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5.2 Target phases of infection
5.2.1 Effect on formation of infectious progeny (II–III)
The impact on production of infectious progeny was studied with the aqueous methanol
extract of Schisandra chinensis berries and the lignan pure compounds. Assaying the extract
at 10–250 μg/ml concentrations, there was no statistically significant difference between
the dose responses of Chlamydia pneumoniae strains  K7  and  CV6  either  at  the  first  or
second passage, indicating that the extract inhibited the formation of the second progeny at
the same intensity as the first passage at 250 μg/ml concentration (Figure 4.). Inhibition of
the second passage was statistically significant at the assayed concentrations of ? 50 μg/ml,
P < 0.01–0.001, with both C. pneumoniae strains. At the first passage the inhibition ranged
from 0.54% to 98.7% for K7 and from 18.4% to 100.0% for CV6. The corresponding figures
at the second passage were 26.9% to 100.0% and -12.7% to 100.0%.
* * * * **** * * * ***
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Figure 4. Chlamydia pneumoniae clinical isolate K7 inhibition with the extract at 250 μg/ml
concentration and the Schisandra lignans at 50 μM concentration. Inhibition percentages
are calculated comparing to the infected non-treated controls. Inhibition of the first passage
was  measured  after  72  h  p.i.  (acute  infection)  and  the  second  passage  after  two  acute
infection cycles (72 + 72 h). All data are means ±SEM (n=4), (* P < 0.05, *** P < 0.001).
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The six lignan pure compounds were assayed on C. pneumoniae infectious progeny
production (Figure 4). Consistent with previous growth inhibition experiments, the
inhibition  at  the  first  passage  at  25  and  50  μM  were  lowest  with  schisandrin  (26.3%  at
highest) and highest with schisandrin C (99.5%, 25 μM), schisandrin B, schisandrin C and
schisantherin A (100.0%, 50 μM), each. The same tendency was seen at the infectious
progeny production as the inhibition percentages were again lowest with schisandrin (45.6%
at highest) and highest with schisandrin C (98.3%, 25 μM) and schisandrin A, schisandrin
C and schisantherin A (100.0%, 50 μM), respectively. Schisandrin C showed the highest
inhibition percentages at both concentrations and both passages.
5.2.2 Delayed administration of compounds (III)
Schisandrin and schisandrin B at a concentration of 50??M were administered to Chlamydia
pneumoniae infected cell cultures 2, 8 and 24?h after the initiation of the infection (Figures
5. and 6.). Delaying the administration of schisandrin B and schisandrin to 8?h did not affect
the lignans’ ability to inhibit C. pneumoniae inclusion formation, and inhibitory activity of
schisandrin B remained over 20% also upon administration of the lignans at 24?h post
infection compared to the uninfected control.
*
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Figure 5. The impact of delayed administration of schisandrin and schisandrin B on
C. pneumoniae K7 inclusion counts. The lignans were administered at 50 μM concentration
at either 2 h, 8 h or 24 h post infection. Data represents mean ± SEM, n = 12 (* P < 0.05,
*** P < 0.001).
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Figure 6. Schisandra lignans inhibit the growth of Chlamydia pneumoniae at different
phases of the chlamydial life-cycle.
5.2.3 Pretreatment of elementary bodies (III)
To study the effect of the extract and the lignans on Chlamydia pneumoniae extracellular
form (elementary body, EB) and its ability to infect host cells, a pretreatment of EBs was
carried out. Schisandra extract at 250 μg/ml concentration inhibited infectivity by 94.6%
(significant, data not shown). The impact of the extract was greater than that of the positive
controls’, 10 μM dithiothreitol (DTT), which inhibited infectivity by 84.0%. When the
chlamydial EB particles were pretreated with the six lignans at 50 μM the chlamydial
infectivity inhibition ranged between 11.2% (schisandrin) and 55.2% (schisandrin B)
(Figures 6. and 7.).
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Figure 7. To evaluate direct effects of the 250 μg/ml extract, 50 μM lignans, 250 μM
ascorbic acid and 10 mM dithiothreitol (DTT) on chlamydial elementary bodies,
C. pneumoniae K7 stocks were diluted in the infection medium to yield a 400 000 IFU/ml
suspension. The IFUs as elementary bodies in the medium were pretreated at +4 °C with
the samples for 1 h prior to the inoculation on HL cell monolayers. Data represents mean ±
SEM, n=12. (* P < 0.05, ** P < 0.01, *** P < 0.001).
5.3 Role of cellular redox status modulation in the antichlamydial
effects (III)
The impact of the lignans on changes in cellular basal reactive oxygen species (ROS) levels
was determined.  HL cells  were loaded with a  profluorescent  ROS probe DCFH-DA and
were exposed to each of the lignans at 50 and 25 μM concentrations. 25 μM schisandrin A
and schisandrin B reduced the amount of intracellular ROS with 30.5% and 32.3%
respectively (P < 0.01), when at 50 μM the change was not statistically significant. In the
presence of 1 mM H2O2, an inductor of intracellular ROS levels, none of the lignans at 25
or  50  μM had  an  effect  on  the  amount  of  intracellular  ROS.  Only  50  μM schisandrin  B
reduced  the  amount  of  ROS  by  6.5% (P < 0.05, Figure 8.) in Chlamydia pneumoniae
infected cells (MOI 1.0). The baseline ROS producing activity was not significantly
increased upon C. pneumoniae infection compared to uninfected controls.
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Figure 8. The impact of the Schisandra lignans on C. pneumoniae induced intracellular ROS
levels. HL cells were loaded with the ROS probe DCFH-DA for 1 h, after which the cells
were infected with C. pneumoniae K7 MOI 1 simultaneously with administration of 50 μM
lignans and incubated for an additional hour before the fluorescent readout. Intracellular
ROS levels  were measured after  2 h post  infection.  10 mM N-acetylcysteine (NAC) was
used as a positive control. Data represent mean ± SEM, n = 4 (* P < 0.05, ** P < 0.01, ***
P < 0.001).
To detect the possible antioxidant effect of Schisandra lignans on C. pneumoniae, common
reducing agents ascorbic acid and N-acetylcysteine (NAC) were assayed against Chlamydia.
The reducing compounds were assayed alone and in combination with schisandrin and
schisandrin B at concentrations generally known effective in diminishing oxidative stress
(Figure  9.).  Ascorbic  acid,  a  mild  and  non-toxic  reducing  substance,  as  well  as  NAC,
showed a remarkably weaker inhibitory action than the lignans alone or in combination with
the lignans. Ascorbic acid at 250 μM concentration produced only 11.4% inhibition (not
significant). NAC had a similar effect with 20.2% inhibition when administered alone at
10 mM concentration. Administering simultaneously with schisandrin and schisandrin B,
neither ascorbic acid nor NAC affected the inhibitory activity the lignans. Inhibition of the
growth of Chlamydia was highest with 50 μM schisandrin B.
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Figure 9. The growth inhibition of C. pneumoniae K7 as % to the infected control in the
presence of 250 μM ascorbic acid, 10 mM N-acetylcysteine (NAC), schisandrin and
schisandrin B. All the experiments are performed in three parallel replicates with 12 samples
(N = 3, n = 12; mean ± SEM), (*** P < 0.001).
5.4 Effect on host cell viability (I–IV)
The host cell viability after treatment with the seven commercial peppermint herbal teas
ranged from 82.4% to 99.4% after 72 h exposure (I). The effect of the Schisandra extract
and the Schisandra lignans on logarithmically dividing cells and confluent cell cultures
were assayed at a density of 5×104 and 6×105 cells per well, respectively (II). The viability
of the 250 μg/ml Schisandra extract treated HL host cells was 90.3% for the confluent cells
and 97.3% for the growing cells, with no statistically significant difference from the non-
treated controls (Table 5.). Host cell viabilities of confluent cells (60 000 cells/well) ranged
from 90.3% to 122.0% and from 72.7% to 97.4% with growing cells (5000 cells/well) when
assayed with Schisandra lignans. The viability of either confluent or growing cells was not
reduced by lignans, except schisandrin, which reduced the viability of the growing cells by
18.9% (P < 0.01).
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5.5 Chlamydia-selectivity of studied extract and compounds (II–
III)
To evaluate the sensitivity of the bacteria to the 250 μg/ml extract, the inhibition was
measured on gram-positive Streptococcus pneumoniae and S. pyogenes, as well as gram-
negative Klebsiella pneumoniae. These pathogens typically cause respiratory tract diseases,
including pneumonia. None of the lignans or the extract inhibited the growth of bacteria
other than Chlamydiae (Table 5.). Growth inhibition of seven other metabolically active
bacterial species was investigated by turbidity measurements and resazurin staining. To
examine the Chlamydia-selectivity of  lignans the bacteria  were assayed at  50 μM of the
lignan against both common gram-negative (Enterobacter aerogenes, Escherichia coli,
Proteus mirabilis, Pseudomonas aeruginosa)  and  gram-positive  (Bacillus subtilis,
Staphylococcus aureus, Staphylococcus epidermis) bacteria. Schisandra lignans did not
show growth inhibition of these bacteria (Table 5.).
5.6 Ligand-based in silico screen (IV)
The Enzo natural compound library of 502 compounds was screened against 19
antichlamydial reference compounds. The reference compounds were our research group’s
previous work and found from the literature (Alvesalo et al., 2006b; Salin et al., 2010;
Hanski et al., 2014; original publication III). The reference compounds belonged to the
chemical classes of lignans, flavones, isoflavones, flavonols, gallates, synthetic coumarins
and synthetic flavonoids. Considering that phenotypic antichlamydial testing of a small
fraction of the library takes at least 72 hours, and thus is not ideal of rational high throughput
screening, the initial screening process was done in silico using ChemGPS-NP
chemography tool (Figure 10., flow chart). The virtual hits were chosen according to their
proximity  to  the  reference  set  of  compounds  calculated  as  Euclidean  distances  (EDs)
(Figure 11.). These virtual hits were selected from the natural product library using
ChemGPS-NP, including three closest compounds to the reference antichlamydial
compounds excluding overlapping compounds that already belonged to the references, as
the same compounds that appeared repeatedly as closest compounds and one already known
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antichlamydial compound (betulin) (Salin et al., 2010). In silico screening of the whole
library resulted in 54 virtual hits that were chosen to be tested further in vitro. The selection
process of virtual hits for antichlamydial testing included also in vitro cytotoxicity testing
to exclude toxic compounds (Figure 10.). Assayed at 50 μM concentration, 27 compounds
were excluded as cytotoxic, and for 27 compounds the host cell viability was ? 75%. The
selected non-cytotoxic virtual hits were assayed against C. pneumoniae clinical isolate K7
at 50 μM concentration. This yielded six identified lead compounds showing ? 50%
C. pneumoniae growth inhibition: jervine, mycophenolic acid (MPA), manool, peganole,
6-acetamido-6-deoxy-castanospermine and catharanthine base (Figure 11.). These
compounds belong to the following chemical groups: steroidal alkaloid, phenolic acid,
diterpene, quinazole, indolizine alkaloid and terpene indole alkaloid, respectively.
Figure 10. Screening process flowchart.
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Figure 11. The chemical space analysis shows the regions populated by the six lead
compounds (IV) (black dots), Schisandra lignans (grey dots) (III), reference compounds
other than Schisandra lignans (faded dots) (IV) and eight commercial antibiotics which
have activity against Chlamydia pneumoniae: azithromycin, ciprofloxacin, doxycycline,
erythromycin, minocycline, ofloxacin, rifampicin and streptomycin (white dots). A PC1
(principal component 1) presents descriptors in size, shape and polarizability, PC2 describes
aromatic- and conjugation-related properties and PC3 lipophilicity, polarity and H-bond
capacity. B PC4 presents flexibility (and rigidity). In general, Schisandra lignans and the
six lead compounds are smaller and slightly more aromatic than commercial antichlamydial
drugs.
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6. DISCUSSION
In this work, the principal source for finding antichlamydial hit and lead compounds was
plant extracts. The commercial peppermint herbal teas were selected as representatives to
the crude drug Mentha × piperita (L.) consisting of samples having both relatively high and
low total polyphenol contents (I). The tea samples which had the highest antichlamydial
activity were high in contents of luteolin and apigenin glycosides. These findings are in
accordance with studies reported earlier in the literature, since these two flavonoids, luteolin
and apigenin as aglycones have been shown to have high antichlamydial activity (Alvesalo
et al., 2006b). Also another species of Menthae, Mentha arvensis (L.) has been shown to
have antichlamydial activity (Salin et al., 2011b). The aqueous methanol extract from
Schisandra chinensis inhibited the growth of Chlamydia pneumoniae and Chlamydia
trachomatis in a dose-dependent manner (II). These results are in line with results obtained
with the isolated pure compounds schisandrin and schisandrin B, which showed a notable
inhibition of the two chlamydial species, with less inhibition activity on C. trachomatis than
C. pneumoniae. These findings, however, do not exclude the possibility of other compounds
in the extracts having antichlamydial potency.
In traditional Chinese medicine (TCM) — and overall in Far East ethnopharmacologically
— the plant Schisandra chinensis (Turcz.) Baill. has commonly been used for hepato-,
neuro- and cardioprotection (Panossian & Wikman, 2008). Although Schisandra lignans
are widely studied there are no previous reports considering their antibacterial effects.
However, some authors have reported on antiviral activities against HIV and some DNA
viruses by the lignans (Chen et al., 1997; Chen et al., 2002; Chen et al., 2006; Yang et al.,
2010; Song et al., 2013). A previously made high content screening (HCS) campaign has
identified schisandrin B as an antichlamydial compound with activity against
C. trachomatis (Hanski et al., unpublished). In the paper III it is shown that the investigated
six lignans exhibit inhibition on chlamydial growth as decreased inclusion counts. This
effect is dose-dependent and demonstrated with two distant, clinically important species of
Chlamydia, C. pneumoniae and C. trachomatis.
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The acute infection protocol (I–IV) mimics the natural acute C. pneumoniae infection, as
the  chlamydial  EBs  are  brought  to  close  proximity  with  the  host  cells  and  allowed  to
internalize for 2 hours. Duration of the acute infection is 72 hours, including the 2 hours
infection period after which the cells are fixed and stained. Quantification of Chlamydia
inclusions is done by a direct fluorescent procedure with a commercial fluorescein-
conjugated monoclonal antibody. Methods based on immunofluorescence and monoclonal
antibodies to detect Chlamydia in cell cultures have high specificity and reproducibility
(Stamm et al., 1983). The infectivity of Chlamydia can be increased with a concentration
of cycloheximide which depresses, but not completely inhibits, the metabolism of the
eucaryotic host cells without affecting prokaryotic cells, like Chlamydia (Ripa & Mårdh,
1977). By this protocol the key antimicrobial parameters effect of a compound, such as IC50,
IC90 and MIC values, as well as the growth curves, can be determined. The protocol gives
a basis for the antichlamydial experiments presented in this thesis.
The six Schisandra lignans inhibited the growth of C. pneumoniae and C. trachomatis in a
dose-dependent manner with MIC values of 50 μM against C. pneumoniae, and one of
them, schisandrin C, a MIC value of 25 μM (III).
Altough the Schisandra lignans’ antichlamydial activity is not outstanding compared to the
current antibiotics in use, they present a new chemical group of compounds for
antichlamydial treatment. All the new antichlamydial agents in early clinical development
are only slight modifications to the existing antibiotics (Golparian et al., 2012;
Gebremedhin, 2012; Georgopapadakou, 2014; Chotikhanatis et al., 2014; Kohlhoff et al.,
2014; van Bambeke, 2015), and therefore susceptible to cross-resistance.
The acute infection cycle of C. pneumoniae is 72 hours, in in vitro experiments termed as
first passage, following the infectious elementary bodies release from the host cells to infect
new host cells allowing the cycle to begin again (second passage). In vitro this method is
used in order to gain a value referred to as the MCC value (minimum chlamydiacidic value),
and has been defined as the concentration that completely inhibited further development of
inclusions (Hammerschlag et al., 1983; Kuo & Grayston, 1988). In other words, it is used
to express the amount of infective progeny after 72 hours infection period (duration of the
acute infection) following another 72 hours infection period.
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The impact on production of infectious progeny was studied with the aqueous methanol
extract of Schisandra chinensis berries  and the lignan pure compounds (II,  III).  As there
was no statistically significant difference between the dose responses of C. pneumoniae
strains K7 and CV6 either at the first or second passage, it can be concluded that the extract
inhibited the formation of the second progeny at the same intensity as the first passage.
With pure compounds, the inhibition against C. pneumoniae at the first passage at 25 μM
ranged from 26.3% (schisandrin) to 99.5%. At the infectious progeny production the same
tendency was seen with inhibition percentages ranging from 45.6% (schisandrin) and 98.3%
(schisandrin C).
It is possible that a compound inhibits the growth of Chlamydia at the first passage, but the
Chlamydia recovers in the second passage of the infection. In an earlier study broad-
spectrum cephalosporins and other lactam antibiotics were assayed against C. trachomatis,
and it was seen that a higher concentration of antibiotics was needed for preventing the
formation of a second passage (Hammerschlag et al., 1983).  In the results presented here
this is not seen. Rather the opposite findings describing this phenomenon can be observed,
as the overall inhibition rates are slightly higher at the second passage.
Administration of the compounds at different time points (for example 2, 6, 12 and 24 hours
p.i., post infection) gives information on the strength of the antichlamydial effect at different
phases of the infection.
The results presented herein demonstrate that Schisandra lignans’ antichlamydial activity
is targeted to the chlamydial growth early/mid-cycle, 2–18 hours p.i. This phase initiates
the rapid logarithmic binary division (Wolf et al., 2000). During the first two hours the EBs
internalize into the host cell. After internalization they remain within individual, tightly
membrane-bound vesicles. By 8 h p.i., differentiation into RBs is evidenced, although some
EBs containing a condensed nucleoid may still be present. At 12 h p.i., the morphologically
typical RBs are observed, and by 19 h p.i., multiplication is in full speed. At 24 to 36 h p.i.
the RBs continue to multiply within the inclusion and no EBs are yet detected. The
inhibitory effect of schisandrin and schisandrin B dramatically drops when they are
administered at 24 h p.i. The next notable change in the developmental cycle is by 48 h p.i.,
as the RBs start to differentiate back into EBs. The division at this phase is asynchronous,
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since although EBs and intermediate developmental forms are detected, some typical RBs
are still in the process of binary fission. By 60 and 72 h p.i. there is an increasing percentage
of EBs ready for exocytosis to release for subsequent rounds of infection. The Schisandra
lignans’ effect is targeted to the early/mid-phase of the infection, which marks the
conversion of EBs into RBs. However, the inhibitory effect is maintained when the lignans
are administered 8 h p.i., a time point in which majority of the EBs have differentiated into
RBs (Wolf et al., 2000).
Besides the inhibitory activity of the studied extracts and compounds on the intracellular
forms of Chlamydia, it is essential to know their effect on the outer cellular EBs. Since these
results demonstrate that the inhibitory effect of the Schisandra lignans on C. pneumoniae
EB pretreatment is significant, it can be concluded that these lignans have inhibiting effect
on the EBs which is not dependent on the host cell. However, as the inhibition is remarkably
higher during the infection, the effect is not specifically targeted to the EBs residing outside
the host cell. The Chlamydia inhibiting effect of quercetin has been shown earlier
(Törmäkangas et al., 2005; Alvesalo et al., 2006b), but the effect on the extracellular
infectious elementary bodies (EBs) has not been studied before. In the publication III it was
shown that quercetin reduces the infectivity by 79%. During the infection 50 μM quercetin
was shown to inhibit the growth of C. pneumoniae by 90% (Alvesalo et al., 2006b).
It has been shown that reducing compounds, such as DTT, are able to disturb the assembly
of MOMP and other disulfide-bridged protein in Chlamydia (Jones 1983; Hackstadt et al.,
1985). As the studied lignans are known for their antioxidant activity (See chapter 2.3.1),
this might explain why some of these lignans show partial inhibition when the EBs are
pretreated with them. In addition, a common reducing agent, ascorbic acid decreased the
infectivity by 27.9% (not statistically significant). Inhibitory effect upon the acute infection
model, on the other hand, might depend on intracellular mechanisms.
Schisandra lignans have been widely studied for their antioxidant and pro-oxidant
properties (Ip & Ko, 1996; Chiu et al., 2006; Chiu et al., 2009; Chiu et al., 2011; Checker
et al., 2012; Zeng et al., 2012). Since C. pneumoniae infection  is  known  to  induce  an
increase  in  host  cell  ROS  levels  and  also  the  extracellular  EB  form  of  the  bacterium  is
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known to be sensitive to reducing agents (Kim et al., 2009; Di Pietro et al., 2013), the
relevance of these aspects in the antichlamydial effect of the lignans was studied.
In this study it was observed that 25 μM schisandrin A and schisandrin B reduced the
amount of basal intracellular ROS levels by 30.5% and 32.3% respectively. At 50 μM
concentration schisandrin B did not have this effect, which was also smaller with
schisandrin A at this concentration. In a study the cellular basal levels of ROS were elevated
by schisandrin B in lymphocytes (Checker et al., 2012). The differing results might be due
to a different cell lines used in these studies. During the Chlamydia pneumoniae infection
(MOI 1.0) only 50 μM schisandrin B modestly reduced the amount of ROS (6.5%, P <
0.05). However, the ROS reducing activity of schisandrin B was higher when the basal ROS
levels were measured. These results suggest that the antichlamydial effect of Schisandra
lignans is not due to interference with the C. pneumoniae-induced ROS production, nor
solely the antioxidant effect. Also the time course of the infection-induced increase in ROS
levels speaks against the ROS-related mechanistic effect of Schisandra lignans. The ROS
levels are normally elevated 1 hour after the first contact between Chlamydia and the host
cell, whereas administration of schisandrin B after 8 hours p.i. still shows efficient inhibition
of the infection. Schisandrin B has been shown to inhibit the production of ROS in microglia
(Zeng et al., 2012). In this study by Zeng et al. NADPH oxidase-dependent superoxide O2
and ROS formation were LPS induced. This result, however, is not directly comparable to
the results gained in this study, because in addition to different cell lines used in these
studies, Zeng et al. used a smaller concentration of schisandrin B (5–20 μM). Moreover, the
ROS production in microglia was induced with LPS produced by Escherichia coli.
Chlamydial LPS is shown to be immunogenically different from other bacterial LPS, in
terms of evoking a weaker immune response (Kalayoglu, et al., 2000).
The common reducing agents ascorbic acid (vitamin C) and N-acetylcysteine (NAC) were
assayed against C. pneumoniae alone and in combination with schisandrin and schisandrin
B. The reducing agents showed a remarkably weaker inhibitory action than the Schisandra
lignans and did not have any synergistic effect when administered with the lignans.
Chlamydia has  intracellular  redox  dependent  mechanisms  that  are  specific  for  its  own
metabolism. C. pneumoniae is shown to induce monocyte oxidation of LDL in a dose-
69
dependent manner (Kalayoglu, 1999). LDL oxidation was enhanced with longer incubation
periods  and  with  increasing  concentrations  of  LDL,  whereas  it  was  inhibited  by  the
antioxidant ?-tocopherol (vitamin E). Since vitamin E inhibits C. pneumoniae-induced
macrophage LDL oxidation, one might assume that also the modest inhibitory action of
vitamin C presented herein stems from the general antioxidative activity of these vitamins.
As Schisandra lignans have various effects on human cells, and some of them are
manipulated by C. pneumoniae, there are several possible mechanisms of action, which
might contribute to the antichlamydial action of Schisandra lignans. According to the
literature  reviewed  in  this  thesis  it  seems  that  the  common  things  between Schisandra
lignans’ and Chlamydia’s effects are, to a large extent, in the host cell’s immunity system
(Table 2.).
Apoptosis is yet another interesting potential target of the Schisandra lignans’ mode of
action. The mammalian cell apoptosis is regulated by pro-apoptotic and anti-apoptotic
signals. Several members of the species Chlamydia, including Chlamydia pneumoniae have
been shown to inhibit the pro-apoptotic signaling molecules, such as Bcl-2 family of
proteins, cytochrome c and caspase-3 pathway (Airenne et al., 2002; Fischer et al., 2004).
The C. pneumoniae infected  host  cells  were  human  laryngeal  carcinoma  cell  line  Hep2
(Fischer  et  al.,  2004).  In  contrast,  schisandrin  B  has  been  shown  to  induce  apoptosis  in
human lung adenocarcinoma A549 cells, by inducing pro-apoptotic components Bax,
cytochrome C and caspase-3 and -9, but decreasing Bcl-2 and proliferating cell nuclear
antigen (PCNA) expression (Lv et al., 2015). However, the net effect of schisandrin B was
an increase of apoptosis as the number of cells died by apoptosis. In this study the apoptosis
mediated by schisandrin B was through mitochondrial pathway. By coincidence,
Chlamydia-inhibited apoptosis was blocked upstream of the mitochondrial activation of
Bax/Bak (Fischer et al., 2004). These results, however, depend largely on the cell line in
question. For example C. pneumoniae has also been shown to induce apoptosis in human
coronary artery endothelial cells (Schöier et al., 2006).
Chlamydia pneumoniae is found to upregulate and downregulate host cellular genes and
proteins in HL cells (Alvesalo et al., 2008; Savijoki et al., 2008). Some of these effects are
contrary to the effects of Schisandra lignan’s. Some of the heat shock proteins (HSPs)
70
function as molecular chaperones. C. pneumoniae is shown to downregulate genes that are
responsible for chaperone regulator activity in HL cells (Alvesalo et al., 2008). Schisandra
lignans in turn are shown to upregulate heat shock proteins Hsp25, Hsp70 and Hsp72 (Chiu
& Ko, 2004; Wu et al., 2004 (Table 2.). C. pneumoniae downregulates these genes 12 hours
post  infection,  which  is  a  time  point  where Schisandra lignans display antichlamydial
activity according to the results presented herein.
Another important transmitters which are affected by Schisandra lignans and also important
for Chlamydia, are calcium ions. In cultured hippocampal neurons schisandrin A
(deoxyschisandrin) inhibited oscillations of intracellular Ca2+ by decreasing the influx of
extracellular calcium and the initiation of action potential (Fu et al., 2008). C. pneumoniae
downregulated genes that code calcium channel regulatory activity in HL cells (Alvesalo et
al., 2008). This effect was measured at 24 hours post infection, which is a time point where
schisandrin B still showed over 20% statistically significant inhibitory activity on the
growth of C. pneumoniae. A study determined the effects of modules associated with
various cellular functions which were activated during C. pneumoniae entry phase,
including calcium transport (Wang et al., 2010). The authors concluded the calcium
transport to be one of the key components for successful C. pneumoniae entry into the host
cell.  Concidering  the  relevance  of  calcium  as  a  target  for  antichlamydial  action  of  a
compound, it should be taken into account that calcium is a very common signaling
transmitter present nearly everywhere in the human body. It is present in intracellular and
extracellular space and its action is regulated by different types of calcium channels, as well
as by the genes that code the activity of these receptors.
It must be kept in mind that the antichlamydial results presented in this thesis are gained in
the presence of cycloheximide, which is a compound that inhibits mammalian protein
synthesis. Therefore it is unlikely that the mechanism of action of the presented
antichlamydial compounds is in mammalian protein synthesis. The results suggest rather
that the principal mechanism of action of Schisandra lignans is in the host cell activated
reticulate bodies. However, the possibility of a host cellular target can not be excluded, since
many cellular events do not require protein synthesis. For example phosphorylation of
certain kinases which are upregulated or downregulated by Schisandra lignans or
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C. pneumoniae, often with opposing effects (Table 2., pages 40–41). These kinases, among
other factors, could be the targets of the antichlamydial mechanism of action of Schisandra
lignans.
The studied Schisandra extract and the lignans did not have an effect on the viability of
logarithmically dividing cells and confluent cells. The only exception was schisandrin,
which reduced the viability of the growing cells by 18.9% (P < 0.01).
These results are in line with the literature, as most of the lignans did not affect the host cell
viabilities at the studied concentrations. Toxicology of these lignans has been studied in in
vitro cell models and in vivo animal studies and considered non-toxic with rats (schisandrin
B 30 mg/kg/day × 2, intraperitoneally), mice (schisandrin B 3 mmol/kg/day × 3, orally,
schisandrin 100 mg/kg) and dogs (10 mg/kg daily for 4 weeks) (Chang et al., 1986; Ip &
Ko., 1996; Lee et al., 2012). Several clinical studies made in the former USSR suggest the
herbal products of Schisandra chinensis to be well tolerated by healthy volunteers (reviewed
in Hancke et al., 1999 and Panossian & Wikman, 2008). In these studies, schisandrin was
not found to induce adverse effects in healthy humans. Schisandrin was administered to a
total of 153 healthy human subjects in doses of 3.6 mg (n = 17), 5 mg (n = 44), 10 mg (n =
47) or 20 mg (n = 45), and only four subjects experienced excitation and three complained
of depression. No drug dependency or significant adverse effects were reported in a study
of 1200 patients with 1162 individuals who had been taking infusions of Schisandra
chinensis leaves regularly for 8 months. Only 38 patients (3.3%) had ceased taking the
infusions because of excitation of the central nervous systems. In another study, no adverse
effects were detected in 415 patients taking Schisandra chinensis seed extract for 1 month
during influenza epidemic. The problem of validating the adverse events or toxicity within
the clinical studies made with Schisandra chinensis herbal products is that they are not
standardized for their content of active lignans and that many of the assays do not include
determination of the lignans present.
The Schisandra extract did not affect the growth of gram-positive Streptococcus
pneumoniae and S. pyogenes, nor the growth of gram-negative Klebsiella pneumoniae. The
three latter pathogens typically cause respiratory tract diseases, including pneumonia.
Schisandra lignans didn’t show growth inhibition of seven other metabolically active gram-
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negative bacterial species Enterobacter aerogenes, Escherichia coli, Pseudomonas
aeruginosa, Proteus mirabilis, nor of the gram-positive bacteria, Bacillus subtilis,
Staphylococcus aureus and S. epidermidis at 50 μM concentrations. Although very useful,
broad-spectrum antibiotics are definitely not completely without problems. The overuse of
them has led to a global problem of antibiotic resistance (Gootz, 2010). Also the use of them
has a significant damaging impact on the human gut microbiota (Rea et al., 2011). It is
suggested that the therapeutic use in the treatment of Clostridium difficile infection in the
gastrointestinal tract may even be compromised by their broad spectrum of activity. The use
of more narrow-spectrum antibiotics could be favored to minimize the collateral damage to
the normal microbiota. In addition, narrow-spectrum antibiotics could be one key solution
to the resistance problem, since they only target a specific pathogen (Lewis, 2013). As
C. pneumoniae alone would most likely be too narrow as a sole indication for an antibiotic,
the indication could possibly be broadened to atypical pneumonia (Hanski & Vuorela,
2014). This would, however, require the efficacy to be shown also against other atypical
respiratory pathogens, such as Legionella pneumophila and Mycoplasma pneumoniae.
The Schisandra lignans identified in this study as highly active antichlamydial compounds
were further utilized for building a reference set of antichlamydial compounds for virtual
screening (VS). The screening process made with ChemGPS-NP resulted in 6 lead
compounds with ? 50% Chlamydia pneumoniae growth inhibition. The compounds are new
antichlamydial compounds belonging to different chemical groups than the reference
compounds.
In 2004 Lipinski and Hopkins described the challenge of drug discovery in the chemical
space to be in identifying those regions that are likely to contain biologically active
compounds, the biologically relevant chemical space (Lipinski & Hopkins, 2004). In the
model presented in paper IV, the close proximity of compounds to the references predicted
very well the biological activity as chlamydial growth inhibition, as the lead compounds
showed good antichlamydial activity. Four of the six lead molecules, jervine, mycophenolic
acid (MPA), manool, and peganole gave close to full inhibition at 100 μM concentration
and three of them at 50 μM concentration, namely jervine, MPA and peganole. The most
active compound was MPA with an IC50 value of 0.31 ± 0.1 μM. In Table 6. there are listed
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different lead mining strategies for C. pneumoniae antichlamydial drug discovery. A
synthesized betulin derivative, betulin dioxime, had an IC50 value of 0.29 μM against strain
CWL-029, defined by the same in vitro method that was used in the work presented in this
thesis (Salin et al., 2011a). The effect is thus comparable with that of MPA, which also had
an IC50 value  in  nanomolar  range.  MPA  was  tested  against  a  clinical  isolate  K7,  which
brings the result slightly closer to the clinical situation. Betulin dioxime had a MIC value
of 1 μM against strain CWL-029, which is exactly the same as that of MPA’s MIC value
against the strain K7. Betulin dioxime was also assayed against a clinical isolate CV6 and
had a MIC value of 2.2 μM. Comparing the lead properties, other than activity, betulin
dioxime has a logP value of 4.9, which is high enough for the compound to have potential
problems in solubility (Salin et al., 2010). As a rule of thumb, a compound with logP value
higher than 2.5 is likely to cross blood brain barrier. This may result in central nervous
system-related adverse effects. The logP value of MPA is 2.92 and it doesn’t have violations
of Lipinsky’s rule of five. Five other antichlamydial compounds that have been found with
different screening methods, 2-arylbenzimidazole 42 (Keurulainen et al., 2010),
benzimidazole MB4 (Alvesalo et al., 2006a), biochanin A (Hanski et al., 2014), linarin
(Salin et al., 2011b) and luteolin (Alvesalo et al., 2006b) were not as potent inhibitors of
the growth of C. pneumoniae as MPA. The result of the ligand-based virtual screening
(LBVS) combined with in vitro validation has proved this method to be an effective strategy
for antichlamydial lead mining.
It is said that one key element in performing LBVS is novelty (Walters et al., 2003). This
is because a similarity metric that is too uniform is prone to identify molecules that are close
analogues of the known ligands used to perform the search.  The reference set of compounds
that  was  used  to  perform  the  search  was  relatively  heterogeneous,  as  it  consisted  of
compounds from different chemical groups, such as flavonoids and lignans, for example.
This resulted in finding hit molecules that are functionally equivalent to the reference set,
but chemically distinct, which brings novelty to the search. A target based virtual screening
approach has been used before in Chlamydia research. In a study of finding antichlamydial
compounds, a similarity based virtual screening approach has been used as a tool for
targeted library design (Alvesalo et al., 2006a). In the ligand-based approach presented in
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this study, the identified ligands occupy the same location in the Euclidean 4-dimensional
chemical space, (Results, Figure 11., page 63). This privileged space can be further used in
medicinal chemistry projects in order of finding new compounds with antichlamydial
activity.
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7. Conclusions
In this work, with the in vitro assays on Chlamydia pneumoniae infection, new lead
compounds were screened for drug discovery process. New biologically active extract and
molecules were found to inhibit the growth of C. pneumoniae. These molecules showed
varying activity on two different strains of C. pneumoniae, CV-6 and a clinical isolate K7.
Especially promising were some of the dibenzocyclooctadiene lignans, Schisandra lignans,
from the berries of Schisandra chinensis (Turcz.) Baill. These compounds were shown to
act at the mid-cycle of the infection, 2–18 hours post infection, the phase which initiates the
rapid binary division and exponential growth. The inhibitory effect of the Schisandra
lignans on pretreated C. pneumoniae elementary bodies (EBs) was significant, indicating
an effect on the EBs independent of the host cell. On the other hand, since the inhibition is
remarkably higher during the infection than in the pretreatment, it can be concluded that the
effect is more targeted to the intracellular forms of the bacteria rather than to the extra
cellular EBs.
Since the C. pneumoniae-induced ROS levels were not affected by Schisandra lignans, the
antichlamydial effect of these lignans is not likely to be due to the direct interference with
the C. pneumoniae-induced ROS production. Moreover, the common reducing agents
ascorbic acid or N-acetylcysteine (NAC) did not show remarkable inhibition of chlamydial
growth, nor did they have any synergistic effect when administered together with the
lignans. These results speak for the antichlamydial mechanism of the lignans to be specific
to the host cell–Chlamydia interaction, rather than dependent on their antioxidative
properties.
The Schisandra lignans showed also inhibitory activity on the sexually transmitted disease-
causing pathogen, Chlmaydia trachomatis. However, the antichlamydial activity against
C. pneumoniae was higher with all of the six lignans. In contrast, the Schisandra extract did
not affect the growth of three common respiratory tract pathogens, and Schisandra lignans
did not inhibit the growth of seven common metabolically active bacterial species. These
results suggest a Chlamydia-selective action of the Schisandra lignans.
77
Most of the lignans did not decrease host cell viability at the studied concentrations. This is
in line with literature, since these lignans are showed to be non-toxic in several in vitro and
in vivo animal studies. Also several clinical studies suggest the herbal products of
Schisandra chinensis to be well tolerated.
As the Schisandra lignans  presented  in  this  study  are  effective  and  selective  growth
inhibitors of Chlamydia pneumoniae,  non-toxic  to  the  human  lung  epithelial  HL cells  at
50 μM concentration, and most of them not violating the Lipinski’s rule of five, these
lignans present excellent lead candidates for further optimization.
The ligand-based virtual screening process with ChemGPS-NP yielded six non-toxic lead
compounds, with a hit rate of 1.2%. These molecules belong to new antichlamydial
chemotypes. The most active compound, mycophenolic acid, had an IC50 value in the
nanomolar range. In the model presented here, the in silico–in vitro-correspondence was
good, since the in silico-calculated proximity of compounds to the reference set predicted
very well the chlamydial growth inhibition. With this screening process, a new chemical
space for antichlamydial compounds was defined, which can be further utilized in future
antichlamydial drug discovery projects.
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